News https://www.tanabe-pharma.com/en/news.html Notice Regarding Completion of Business Transfer of Edaravone https://www.tanabe-pharma.com/en/news/rel_260402.html Wed, 01 Apr 2026 23:30:00 GMT 484f4b5c-6eb9-422e-b0d6-2193d8141ae0 2026-04-01T23:30:00Z Notice of Dissolution of Joint Venture relationship with respect to BIKEN Co., Ltd. https://www.tanabe-pharma.com/en/news/rel_260331.html Tue, 31 Mar 2026 02:00:00 GMT f43105fd-d9aa-4790-b690-9a18e2b26c42 2026-03-31T02:00:00Z Tanabe Pharma Announces Positive Data from Phase 3 INSPIRE Study of Dersimelagon in EPP and XLP https://www.tanabe-pharma.com/en/news/rel_260330.html Mon, 30 Mar 2026 06:00:00 GMT dbd589a4-8b9a-4126-a2ae-9116027cef75 2026-03-30T06:00:00Z Announcement of Organizational Changes and Personnel Changes https://www.tanabe-pharma.com/en/news/rel_260202.html Mon, 02 Feb 2026 06:00:00 GMT 3ec2c107-aa76-4fa0-96d8-ee38e21a3738 2026-02-02T06:00:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/upd_260202.html Mon, 02 Feb 2026 00:00:00 GMT 3c934531-99db-4eeb-a935-8db732cc73e5 2026-02-02T00:00:00Z MT-2111 (loncastuximab tesirine-lpyl) Achieved Primary Endpoint in Phase 2 part of Japanese Phase 1/2 study for Relapsed or Refractory Diffuse Large B-cell Lymphoma https://www.tanabe-pharma.com/en/news/rel_260129.html Thu, 29 Jan 2026 02:00:00 GMT 494e38b0-6f57-4e46-937a-43b842fae2ac 2026-01-29T02:00:00Z MT-7117 Demonstrates Positive Topline Results in Development for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) https://www.tanabe-pharma.com/en/news/rel_260115.html Thu, 15 Jan 2026 02:00:00 GMT e49ae09b-de5f-43bf-a70b-783b1f4f9d06 2026-01-15T02:00:00Z Announcement of Personnel Changes https://www.tanabe-pharma.com/en/news/rel_251225.html Thu, 25 Dec 2025 02:00:00 GMT 2138c483-dc31-4ba1-aa0a-5d6521d145f4 2025-12-25T02:00:00Z Notice Regarding Execution of Transfer the RADICAVA Business https://www.tanabe-pharma.com/en/news/rel_251222.html Mon, 22 Dec 2025 10:00:00 GMT 6dff4d53-e11f-40d1-9703-46de611a9a5c 2025-12-22T10:00:00Z Radicut Suspension Approved in Korea for the Treatment of ALS https://www.tanabe-pharma.com/en/news/rel_251212.html Fri, 12 Dec 2025 02:00:00 GMT 8c9da62b-c274-453e-82e9-1ee3a6fbf63c 2025-12-12T02:00:00Z Notice: Tokyo Head Office to be Relocated https://www.tanabe-pharma.com/en/news/rel_251201.html Mon, 01 Dec 2025 01:00:00 GMT a2bbd96d-2ad1-4579-89e0-7005612674dc 2025-12-01T01:00:00Z Anti-CD19 monoclonal antibody UPLIZNAⓇ for I.V. Infusion 100mg Approval for additional indication of suppression of relapse of immunoglobulin G4-related disease in Japan ～Japan’s First Drug Approved for IgG4-Related Disease～ https://www.tanabe-pharma.com/en/news/news20251120140000.html Thu, 20 Nov 2025 05:00:00 GMT ed84bdb4-1d56-45a8-9ae4-3c73ed9f04bf 2025-11-20T05:00:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news202511051030447.html Wed, 05 Nov 2025 01:30:00 GMT e38eb6c0-8751-4a2d-898b-dc09f970a86d 2025-11-05T01:30:00Z Launch of Tanabe Pharma’s Teaser Website https://www.tanabe-pharma.com/en/news/info251104.html Tue, 04 Nov 2025 01:00:00 GMT 2d138f69-c786-4315-b913-8243fc425556 2025-11-04T01:00:00Z Official Approval of Company Name Change to “Tanabe Pharma” https://www.tanabe-pharma.com/en/news/news20251031103504.html Fri, 31 Oct 2025 01:00:00 GMT 93dda7a4-9d3c-4870-9159-1f73eea4a850 2025-10-31T01:00:00Z Receipt of Complete Response Letter from U.S. FDA for investigational ND0612 https://www.tanabe-pharma.com/en/news/news20251023103060.html Thu, 23 Oct 2025 01:00:00 GMT ad18948e-144a-4938-b4e9-a96c65a2cfa4 2025-10-23T01:00:00Z Announcement of Personnel Changes https://www.tanabe-pharma.com/en/news/news20251020347658.html Mon, 20 Oct 2025 01:30:50 GMT 46531910-d65b-4a2a-9e75-80765b2aed65 2025-10-20T01:30:50Z Anti-CD19 monoclonal antibody UPLIZNA® for I.V. Infusion 100mg Application for additional indication of generalized Myasthenia Gravis in Japan https://www.tanabe-pharma.com/en/news/news20251014103099.html Tue, 14 Oct 2025 01:00:00 GMT 66ba83cc-39c2-491e-9320-f7b70ccf93b9 2025-10-14T01:00:00Z Announcement of Organizational Changes and Personnel Change https://www.tanabe-pharma.com/en/news/news20250922209572.html Mon, 22 Sep 2025 01:00:44 GMT 425b11a6-a245-4b49-9d75-3bb3dfea5046 2025-09-22T01:00:44Z Expiration of Co-Promition Agreement for STELARA® (ustekinumab) https://www.tanabe-pharma.com/en/news/news20250916012230.html Tue, 16 Sep 2025 01:30:56 GMT 6b5c0c04-edea-4121-acd3-0ca3d5d8e522 2025-09-16T01:30:56Z Announcement of launch of Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug " CANALIA® Combination OD Tablets " ～Adoption of a printing design with enhanced identifiability and visibility～ https://www.tanabe-pharma.com/en/news/news20250902103028.html Tue, 02 Sep 2025 01:30:00 GMT 50736d90-1fb2-46f4-862b-346d3644739b 2025-09-02T01:30:00Z Change in Representative Director, New Executive Team and Management Structure https://www.tanabe-pharma.com/en/news/news20250829103049.html Fri, 29 Aug 2025 01:30:00 GMT 672832ad-1e9f-423e-95cc-47e09971949f 2025-08-29T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20250801103046.html Fri, 01 Aug 2025 01:30:00 GMT 96582a6d-e227-4ade-99ad-49f21747e9fc 2025-08-01T01:30:00Z To initiate joint research aiming to create innovative cancer drugs in Targeted Alpha Therapy https://www.tanabe-pharma.com/en/news/news20250710103033.html Thu, 10 Jul 2025 01:30:00 GMT 3a65f18d-2f92-4b54-a524-0289de7d96f9 2025-07-10T01:30:00Z Mitsubishi Tanabe Pharma to Begin a New Chapter under Bain Capital Ownership -Company Name Change to “Tanabe Pharma Corporation” Effective December 1, 2025- https://www.tanabe-pharma.com/en/news/news20250701103099.html Tue, 01 Jul 2025 01:30:00 GMT 86eb5e0b-1eff-4267-ba12-a79bc266b62e 2025-07-01T01:30:00Z Appointment of Directors and Executive Officers https://www.tanabe-pharma.com/en/news/news20250701102910.html Tue, 01 Jul 2025 01:29:00 GMT 93940606-ed94-47eb-8a24-2d28bf6a1055 2025-07-01T01:29:00Z Initiation of Phase 1/2 clinical trial of MT-4561 for Advanced Solid Tumors https://www.tanabe-pharma.com/en/news/news20250613103055.html Fri, 13 Jun 2025 01:30:00 GMT 7ad27cf8-c862-47c4-a1b7-1cabdada7e41 2025-06-13T01:30:00Z U.S. FDA Accepts Resubmission for ND0612, an Investigational Treatment for Motor Fluctuations in Parkinson’s Disease https://www.tanabe-pharma.com/en/news/news20250529103046.html Thu, 29 May 2025 01:30:00 GMT 0ce80e01-3dab-487a-80df-674a41368f4d 2025-05-29T01:30:00Z Launch of Radicava® for the Treatment of ALS in Australia https://www.tanabe-pharma.com/en/news/news20250527103046.html Tue, 27 May 2025 01:30:00 GMT 6c38132d-ee6f-42b0-827e-0db1ed230f15 2025-05-27T01:30:00Z Announcement of Personnel Changes https://www.tanabe-pharma.com/en/news/news20250526103032.html Mon, 26 May 2025 01:30:00 GMT b1322fa8-4080-4c2d-884f-5088923ffe99 2025-05-26T01:30:00Z Appointment of Directors https://www.tanabe-pharma.com/en/news/news20250520103089.html Tue, 20 May 2025 01:30:00 GMT 27270f2b-572f-43c7-8d83-9788bb4436b2 2025-05-20T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20250513103010.html Tue, 13 May 2025 01:30:00 GMT 6d8406ec-d9de-45f8-a7ee-4e09ddc93d3d 2025-05-13T01:30:00Z CANAGLU Tablets 100mg, a sodium glucose co-transporter 2 (SGLT2) inhibitor in Thailand Mitsubishi Tanabe Pharma Thailand now started marketing https://www.tanabe-pharma.com/en/news/news20250509103067.html Fri, 09 May 2025 01:30:00 GMT 8bf06a57-38c7-43e2-8a20-6cbf8a8c66d7 2025-05-09T01:30:00Z Anti-CD19 monoclonal antibody UPLIZNA® for I.V. Infusion 100mg Application for additional indication of immunoglobulin G4-related disease in Japan https://www.tanabe-pharma.com/en/news/news20250321103078.html Fri, 21 Mar 2025 01:30:00 GMT 65cd5905-22b9-4403-a4c5-096b59e24e4d 2025-03-21T01:30:00Z Announcement of NHI Price Listing and Release Date of “Zepbound®”, a Long-Acting GIP/GLP-1 Receptor Agonist, for the Chronic Disease of “Obesity Disease” with Multiple Factors https://www.tanabe-pharma.com/en/news/news20250319103074.html Wed, 19 Mar 2025 01:30:00 GMT b50547be-726e-4cc7-a69e-fba86908f051 2025-03-19T01:30:00Z Filling for a Oral Edaravone Formulation for the treatment of ALS in Korea https://www.tanabe-pharma.com/en/news/news20250313103044.html Thu, 13 Mar 2025 01:30:00 GMT ec36e1af-0963-4038-aba0-3605e3fcaf58 2025-03-13T01:30:00Z Regulatory Approval of Cariprazine (MP-214) For Adjunctive therapy for major depressive disorder in Thailand https://www.tanabe-pharma.com/en/news/news20250228103076.html Fri, 28 Feb 2025 01:30:00 GMT e7cacda0-ce72-45b0-8878-d2b28479c3c1 2025-02-28T01:30:00Z EMA Accepts Marketing Authorization Application for ND0612, an Investigational Treatment for Motor Fluctuations in Parkinson’s Disease https://www.tanabe-pharma.com/en/news/news20250221103074.html Fri, 21 Feb 2025 01:30:00 GMT 9112f1f0-1e86-418c-8aa3-93ab08340888 2025-02-21T01:30:00Z Announcement of Organizational Changes and Personnel Changes of the Mitsubishi Chemical Group https://www.tanabe-pharma.com/en/news/info250220.html Thu, 20 Feb 2025 01:30:00 GMT e52376ac-82ce-42c3-b2f0-bcb125ab7ad3 2025-02-20T01:30:00Z Additional Approval of Dosage Form of CANALIA® Combination OD Tablets, Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug ~ First OD Tablets of Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug in Japan ~ https://www.tanabe-pharma.com/en/news/news20250217103079.html Mon, 17 Feb 2025 01:30:00 GMT 709adb2c-6661-4c58-9aaa-25fdd4b677d8 2025-02-17T01:30:00Z Notice Concerning the Transfer of Mitsubishi Tanabe Pharma Corporation and its Subsidiaries https://www.tanabe-pharma.com/en/news/info250207.html Fri, 07 Feb 2025 01:30:00 GMT fccba010-fcb8-46f5-8ad7-28f1b2c63fb0 2025-02-07T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20250206103039.html Thu, 06 Feb 2025 01:30:00 GMT 2c3e93af-144c-4a44-87fa-24fe3c7a0794 2025-02-06T01:30:00Z Sub-licensing Agreement for the Oral Spleen Tyrosine Inhibitor Fostamatinib in Taiwan with Kissei Pharmaceutical https://www.tanabe-pharma.com/en/news/news20250107103033.html Tue, 07 Jan 2025 01:30:00 GMT b58ac7c4-a6e4-4ef7-8c8c-22d9c0cb96f0 2025-01-07T01:30:00Z "Zepbound®", a Long-Acting GIP/GLP-1 Receptor Agonist, Approved for the Chronic Disease of "Obesity Disease" with Multiple Factors https://www.tanabe-pharma.com/en/news/news20241227103051.html Fri, 27 Dec 2024 01:30:00 GMT 8e7ea561-bca7-438a-bb5c-800dcf65364c 2024-12-27T01:30:00Z Announcement of Organizational Changes and Personnel Changes of the Mitsubishi Chemical Group https://www.tanabe-pharma.com/en/news/news20241212103080.html Thu, 12 Dec 2024 01:30:00 GMT dd34905d-2989-4152-b993-2af5e000cc1c 2024-12-12T01:30:00Z Mitsubishi Tanabe Pharma Corporation Entered into Research Collaboration with Dewpoint to Advance Small Molecule Condensate Modulator for ALS https://www.tanabe-pharma.com/en/news/news20241205103040.html Thu, 05 Dec 2024 01:30:00 GMT 3602df6f-7f95-48cb-b603-beeb725ed612 2024-12-05T01:30:00Z Sustainability Information https://www.tanabe-pharma.com/en/news/news20241129103036.html Fri, 29 Nov 2024 01:30:00 GMT 1bd6eadb-a444-4979-95ab-3be0c063ca92 2024-11-29T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20241101103088.html Fri, 01 Nov 2024 01:30:00 GMT efed1743-bc9d-4cdf-a816-49d359a462c8 2024-11-01T01:30:00Z Update on U.S. Development Plan of Investigational ND0612 for the Treatment of Motor Fluctuations in People with Parkinson’s Disease https://www.tanabe-pharma.com/en/news/news20241101102942.html Fri, 01 Nov 2024 01:29:00 GMT a70d9e95-880a-4351-8c48-b359e605dd32 2024-11-01T01:29:00Z Termination of Exclusive Sales Rights Agreements for HGF Gene Therapy Product "Collategene®" in Japan and the US https://www.tanabe-pharma.com/en/news/news20240823103027.html Fri, 23 Aug 2024 01:30:00 GMT 2e4cc59b-618c-4943-a6c1-b79f872d33c0 2024-08-23T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20240801103092.html Thu, 01 Aug 2024 01:30:00 GMT 51b5b93e-94c3-4d4a-b49b-6eb9158a68f0 2024-08-01T01:30:00Z Notice Regarding Implementation of Voluntary Retirement Program https://www.tanabe-pharma.com/en/news/news20240729103029.html Mon, 29 Jul 2024 01:30:00 GMT 437d26c4-126a-4ba6-945c-82cc62ce7123 2024-07-29T01:30:00Z Moderna And Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines https://www.tanabe-pharma.com/en/news/news20240709103017.html Tue, 09 Jul 2024 01:30:00 GMT 20bbe6e9-b2dd-4253-8e66-827bdb26c050 2024-07-09T01:30:00Z Distribution Discontinuation of HGF gene therapy product "Collategene®", following withdrawal of the manufacturing and marketing approval application https://www.tanabe-pharma.com/en/news/news20240624103068.html Mon, 24 Jun 2024 01:30:00 GMT 8d175f32-68b4-45b4-a5aa-5d93b00520d6 2024-06-24T01:30:00Z Transfer of Argatroban Business in Europe https://www.tanabe-pharma.com/en/news/news20240617103015.html Mon, 17 Jun 2024 01:30:00 GMT eba9aa7c-1d92-4d06-bf1c-99a738c85cb6 2024-06-17T01:30:00Z Receipt of Complete Response Letter from U.S. FDA for ND0612 https://www.tanabe-pharma.com/en/news/news20240611103066.html Tue, 11 Jun 2024 01:30:00 GMT da9b9545-c9d7-4883-b6df-e85e28f3f97f 2024-06-11T01:30:00Z Announcement of launch of SGLT2 inhibitor "CANAGLU® OD Tablets" ～Adoption of Environmentally Friendly Biomass-plastic PTP Sheets～ https://www.tanabe-pharma.com/en/news/news20240522103013.html Wed, 22 May 2024 01:30:00 GMT 1dc77142-9735-4131-94e2-00515d4d34d7 2024-05-22T01:30:00Z Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis, goes on sale in Japan-World-first cream-type allergic conjunctivitis treatment requiring just once daily administration to the upper and lower eyelids- https://www.tanabe-pharma.com/en/news/news20240522102952.html Wed, 22 May 2024 01:29:00 GMT 7828ce2c-67ad-4da3-942f-a186501a700b 2024-05-22T01:29:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20240515103097.html Wed, 15 May 2024 01:30:00 GMT d804c66a-3d77-472f-9879-36063056f417 2024-05-15T01:30:00Z The Global Health Innovative Technology Fund provides grant to Mitsubishi Tanabe Pharma and DNDi for Chagas disease drug discovery https://www.tanabe-pharma.com/en/news/news20240509103055.html Thu, 09 May 2024 01:30:00 GMT 9b7a43b3-1c2c-4305-91b8-0cf113f031e0 2024-05-09T01:30:00Z Announcement of Approval Submission and Marketing Alliance in Japan for Tirzepatide as a Drug for Obesity Disease https://www.tanabe-pharma.com/en/news/news20240508103060.html Wed, 08 May 2024 01:30:00 GMT 4b2ced6a-39d7-4703-8a7d-12227472d13f 2024-05-08T01:30:00Z Santen and Mitsubishi Tanabe Pharma announce the conclusion of a contract for the joint sales promotion in Japan of Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis https://www.tanabe-pharma.com/en/news/news20240507103050.html Tue, 07 May 2024 01:30:00 GMT 910bfd33-cc0f-4980-8f8e-3ad78d5489ee 2024-05-07T01:30:00Z RADICAVA ORS® as Orphan drug designation and approval in US https://www.tanabe-pharma.com/en/news/news20240409103024.html Tue, 09 Apr 2024 01:30:00 GMT 8a236793-2ab6-46a1-b7fb-f83d0cd72930 2024-04-09T01:30:00Z Announcement of Publication in The Lancet Neurology from the Clinical Study of Investigational ND0612 for Parkinson's Disease https://www.tanabe-pharma.com/en/news/news20240319103061.html Tue, 19 Mar 2024 01:30:00 GMT 77907d0e-9da8-4239-8770-6da83561d15a 2024-03-19T01:30:00Z Additional Approval of SGLT2 inhibitor CANAGLU® OD Tablets～First OD Tablets of SGLT2 inhibitors in Japan～ https://www.tanabe-pharma.com/en/news/news20240318103020.html Mon, 18 Mar 2024 01:30:00 GMT 102d4269-4abb-445a-8160-605907e83fe9 2024-03-18T01:30:00Z Launch of "GOBIK Aqueous Suspension Syringes", Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine https://www.tanabe-pharma.com/en/news/news20240315103066.html Fri, 15 Mar 2024 01:30:00 GMT 7b3602b6-1034-4e50-9ec3-8a7ea663c422 2024-03-15T01:30:00Z Expiration of Marketing Alliance Agreement for TENELIA® Tablets, TENELIA® OD Tablets and CANAGLU® Tablets https://www.tanabe-pharma.com/en/news/news20240304103042.html Mon, 04 Mar 2024 01:30:00 GMT 4ebefad8-85a0-423d-a804-b2ef8c24d64f 2024-03-04T01:30:00Z Announcement of Organizational Changes and Personnel Changes of the Mitsubishi Chemical Group https://www.tanabe-pharma.com/en/news/news20240227103069.html Tue, 27 Feb 2024 01:30:00 GMT 2ae261b3-fd33-4ac8-ac3d-b98efddb3299 2024-02-27T01:30:00Z Launch of Radicava® for the Treatment of ALS in Brazil～First successful launch by a partner in global expansion～ https://www.tanabe-pharma.com/en/news/news20240227102932.html Tue, 27 Feb 2024 01:29:00 GMT f2d62565-a5e9-4619-940f-8d39c1f8900a 2024-02-27T01:29:00Z Application for Additional Dosage Form of CANALIA® Combination OD Tablets, Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug https://www.tanabe-pharma.com/en/news/news20240220103024.html Tue, 20 Feb 2024 01:30:00 GMT 98f63f5e-a015-4711-9765-7d332c78d942 2024-02-20T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20240206103022.html Tue, 06 Feb 2024 01:30:00 GMT 9fd94af5-53d3-4b50-bb90-5a6a13e021b8 2024-02-06T01:30:00Z Transfer of Three Marketed Products in Japan https://www.tanabe-pharma.com/en/news/news20240129103082.html Mon, 29 Jan 2024 01:30:00 GMT f9dffa44-f324-47d1-8f1a-8d9186205d16 2024-01-29T01:30:00Z Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund's third phase ―Targeting treatments for infectious diseases that burden the developing world― https://www.tanabe-pharma.com/en/news/news20240126103029.html Fri, 26 Jan 2024 01:30:00 GMT e2b40a9e-9f2a-4124-a742-b8ee695ac833 2024-01-26T01:30:00Z Co-promotion of "GOBIK Aqueous Suspension Syringes", Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine https://www.tanabe-pharma.com/en/news/news20240123103036.html Tue, 23 Jan 2024 01:30:00 GMT e7587bea-5003-4634-9f3a-e4758599a2f4 2024-01-23T01:30:00Z Execution of Share Transfer Agreement on Overseas Joint Venture Subsidiary https://www.tanabe-pharma.com/en/news/news20231221103045.html Thu, 21 Dec 2023 01:30:00 GMT 82fff562-d67a-4069-a090-f3436718ff1c 2023-12-21T01:30:00Z The mechanism of intracellular glucose uptake of SGLT2 was elucidated by Cryo-electron Microscopy analysis in a joint study with the University of Tokyo Published in Nature Structural & Molecular Biology https://www.tanabe-pharma.com/en/news/news20231207103064.html Thu, 07 Dec 2023 01:30:00 GMT 921776d7-53cc-486b-89c3-075766e7fe5b 2023-12-07T01:30:00Z Launch of UPLIZNA® for Neuromyelitis Optica Spectrum Disorder in Taiwan https://www.tanabe-pharma.com/en/news/news20231130103027.html Thu, 30 Nov 2023 01:30:00 GMT 7ecff7d2-e6b2-44be-b733-d10c4539113c 2023-11-30T01:30:00Z Mitsubishi Tanabe Pharma Corporation Entered into License Agreement with Kynexis for Neuropsychiatric Drug Candidate “MT-5356” https://www.tanabe-pharma.com/en/news/news20231108103038.html Wed, 08 Nov 2023 01:30:00 GMT 3717ee16-c91d-49fa-87ef-fd2e78123b34 2023-11-08T01:30:00Z Sustainability Information https://www.tanabe-pharma.com/en/news/news20231107103075.html Tue, 07 Nov 2023 01:30:00 GMT adb25338-dbb3-4998-bbbf-3886d3149845 2023-11-07T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20231101103064.html Wed, 01 Nov 2023 01:30:00 GMT 12d14813-f6ef-4fb1-98cd-8bcf9ac99ed4 2023-11-01T01:30:00Z A Global Phase 3 Clinical Trial of MT-2111 in Combination with Rituximab has been started in Japan https://www.tanabe-pharma.com/en/news/news20231025103077.html Wed, 25 Oct 2023 01:30:00 GMT 597c6e29-5346-4173-8ad4-da416dfc6f76 2023-10-25T01:30:00Z MT-2111 in Phase 2 part of Phase 1/2 Clinical Trial in Diffuse Large B-cell Lymphoma in Japan https://www.tanabe-pharma.com/en/news/news20231018103019.html Wed, 18 Oct 2023 01:30:00 GMT 6b6db227-16ef-406f-8760-19943da4ef5d 2023-10-18T01:30:00Z Merger of Wholly Owned Subsidiary https://www.tanabe-pharma.com/en/news/news20231004103017.html Wed, 04 Oct 2023 01:30:00 GMT 2c5d25c9-89c3-4745-b574-a03ab67bb19a 2023-10-04T01:30:00Z The Global Health Innovative Technology Fund provides grant for joint research into anti-malarial drugs with novel mechanisms of action conducted by Mitsubishi Tanabe Pharma and a malaria research institution https://www.tanabe-pharma.com/en/news/news20230927103033.html Wed, 27 Sep 2023 01:30:00 GMT 1d7c8191-95b9-4e48-ac57-4f6237d3d509 2023-09-27T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20230802103032.html Wed, 02 Aug 2023 01:30:00 GMT b3aa3351-794e-4916-bb98-07009ce22765 2023-08-02T01:30:00Z Global, Phase 3b study of Oral Edaravone in ALS https://www.tanabe-pharma.com/en/news/news20230801103021.html Tue, 01 Aug 2023 01:30:00 GMT e73d211f-c36f-4104-9383-cb89a5c83087 2023-08-01T01:30:00Z Launch of REMLEAS® capsules 40mg for Treatment of Tardive Dyskinesia in three ASEAN countries https://www.tanabe-pharma.com/en/news/news20230731103071.html Mon, 31 Jul 2023 01:30:00 GMT 05fa3fe8-3834-4c6d-ba06-c4cbf6999fff 2023-07-31T01:30:00Z MPH was Selected for AMED's Strengthening Program for Pharmaceutical Startup Ecosystem Initiative https://www.tanabe-pharma.com/en/news/news20230616103090.html Fri, 16 Jun 2023 01:30:00 GMT ff9cbf7a-cc85-47ec-97db-bc8ef5fc4522 2023-06-16T01:30:00Z New Launch of Mounjaro® 7.5mg/10mg/12.5mg/15mg Ateos®, the World's First Sustained Release GIP/GLP-1 Receptor Agonist Full Lineup Now Available https://www.tanabe-pharma.com/en/news/news20230612103079.html Mon, 12 Jun 2023 01:30:00 GMT 75879a3e-1f99-4ebf-84be-274bd12e7acc 2023-06-12T01:30:00Z AnGes filed for approval of its HGF gene therapy product Collategene® for the first time since the introduction of the conditional/time-limited authorization system for regenerative medicine products https://www.tanabe-pharma.com/en/news/news20230531103045.html Wed, 31 May 2023 01:30:00 GMT 2f3f7041-6be9-47ab-86fc-c999ea9ae168 2023-05-31T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20230512103089.html Fri, 12 May 2023 01:30:00 GMT 37651e28-a0aa-4ca4-9947-2a9b002e6712 2023-05-12T01:30:00Z RADICAVA® Oral Suspension Approved in Switzerland for the Treatment of ALS https://www.tanabe-pharma.com/en/news/news20230511103082.html Thu, 11 May 2023 01:30:00 GMT 981a3c0e-1b56-49a6-a82e-f48be526badf 2023-05-11T01:30:00Z New launch of Mounjaro® 2.5mg/5mg Ateos®, the world's first sustained release GIP/GLP-1 receptor agonist https://www.tanabe-pharma.com/en/news/news20230418103060.html Tue, 18 Apr 2023 01:30:00 GMT 5c65ec11-1eb6-4dea-82bf-c6cf1f38dbca 2023-04-18T01:30:00Z For the Treatment of ALS, Edaravone RADICUT® Oral Suspension 2.1% Now Available in Japan https://www.tanabe-pharma.com/en/news/news20230417103083.html Mon, 17 Apr 2023 01:30:00 GMT cc241ae3-5c64-4a9c-8d31-aaa9f77f19b6 2023-04-17T01:30:00Z Support for the Earthquake Victims in Turkey and Syria https://www.tanabe-pharma.com/en/news/news20230411103063.html Tue, 11 Apr 2023 01:30:00 GMT e44dda6e-037b-4819-8615-d34ff5134c7f 2023-04-11T01:30:00Z Anti-cytomegalovirus chemotherapeutic agent "Valixa® Dry Syrup 5000mg" Approved for the indication of symptomatic congenital cytomegalovirus infection in Japan https://www.tanabe-pharma.com/en/news/news20230327103066.html Mon, 27 Mar 2023 01:30:00 GMT edcd1889-5fb4-4af3-83f9-3621c69f5396 2023-03-27T01:30:00Z Approval of "GOBIK Aqueous Suspension Syringes", Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine https://www.tanabe-pharma.com/en/news/news20230327102957.html Mon, 27 Mar 2023 01:29:00 GMT 30994656-2d2d-4d0a-9320-10c3c775a6bc 2023-03-27T01:29:00Z Notification of Application for Additional Dosage Form of SGLT2 inhibitor CANAGLU® OD Tablets 100 mg https://www.tanabe-pharma.com/en/news/news20230320103018.html Mon, 20 Mar 2023 01:30:00 GMT aae32ebd-ddb2-443a-a05c-3195cf961ac8 2023-03-20T01:30:00Z Announcement of Organizational Changes and Personnel Changes of the Mitsubishi Chemical Group https://www.tanabe-pharma.com/en/news/news20230228103073.html Tue, 28 Feb 2023 01:30:00 GMT b4264d0d-bec4-4ba6-83aa-a85eb71db418 2023-02-28T01:30:00Z Mitsubishi Chemical Group ― Notice on Revision to Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2023 https://www.tanabe-pharma.com/en/news/news20230216103013.html Thu, 16 Feb 2023 01:30:00 GMT a750e417-8cb1-4796-badf-8dc68d578217 2023-02-16T01:30:00Z Mitsubishi Chemical Group ― Notice of Award for the Arbitration Filed against Mitsubishi Tanabe Pharma Corporation, a Consolidated Subsidiary https://www.tanabe-pharma.com/en/news/news20230214103024.html Tue, 14 Feb 2023 01:30:00 GMT f61f81f0-f5a4-42dd-adb7-346c93964041 2023-02-14T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20230207103029.html Tue, 07 Feb 2023 01:30:00 GMT 01dc0efd-b036-472f-8cd9-7b5e9c703e12 2023-02-07T01:30:00Z Overseas Consolidated Subsidiary, Medicago to Cease Operations https://www.tanabe-pharma.com/en/news/news20230203103060.html Fri, 03 Feb 2023 01:30:00 GMT a34c0616-05a4-477c-bdf2-5fbb85fbc998 2023-02-03T01:30:00Z Mitsubishi Chemical Group Announces New Group Concept (Purpose, Slogan, Our Way) https://www.tanabe-pharma.com/en/news/news20230126103046.html Thu, 26 Jan 2023 01:30:00 GMT 417cc1e6-545e-4893-a341-77ea4b355194 2023-01-26T01:30:00Z Personnel Changes of the Mitsubishi Chemical Group https://www.tanabe-pharma.com/en/news/news20230120103075.html Fri, 20 Jan 2023 01:30:00 GMT 6f51d502-8334-4fc2-9ee8-1b12a472ffab 2023-01-20T01:30:00Z Announcement of Positive Results from the Phase 3 Clinical Trials of Parkinson's Disease Drug Candidate ND0612 https://www.tanabe-pharma.com/en/news/news20230110103092.html Tue, 10 Jan 2023 01:30:00 GMT e07dbb15-ac38-4f16-8c97-d819e8043fb5 2023-01-10T01:30:00Z For Treatment of ALS, Edaravone RADICUT® Oral Suspension 2.1% Approved in Japan https://www.tanabe-pharma.com/en/news/news20221223103013.html Fri, 23 Dec 2022 01:30:00 GMT 9c2b45d5-4d8d-49fc-8b18-888a791961c8 2022-12-23T01:30:00Z GARDP and Mitsubishi Tanabe Pharma Corporation announce partnership in search for new antibiotics https://www.tanabe-pharma.com/en/news/news20221124103041.html Thu, 24 Nov 2022 01:30:00 GMT ff2cc15a-0ca8-4860-90e2-bc69ee38072b 2022-11-24T01:30:00Z Sustainability Information https://www.tanabe-pharma.com/en/news/news20221121103056.html Mon, 21 Nov 2022 01:30:00 GMT 6991d1f8-8698-46cc-8075-fa62ab728cd7 2022-11-21T01:30:00Z RADICAVA® Oral Suspension Approved in Canada for the Treatment of ALS https://www.tanabe-pharma.com/en/news/news20221109103074.html Wed, 09 Nov 2022 01:30:00 GMT 2db97378-114f-4bf3-89a8-36ca0d2bdd4d 2022-11-09T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20221108103061.html Tue, 08 Nov 2022 01:30:00 GMT e0be4d28-abbc-40b2-9da3-fc9822d3aa77 2022-11-08T01:30:00Z Inebilizumab has received import and marketing permission in Taiwan for Neuromyelitis Optica Spectrum Disorder https://www.tanabe-pharma.com/en/news/news20221017103082.html Mon, 17 Oct 2022 01:30:00 GMT 5bec72cb-53ac-4466-a9cb-8c61d27d10f4 2022-10-17T01:30:00Z Approval of Mounjaro, the world's first sustained release GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes in Japan https://www.tanabe-pharma.com/en/news/news20220926103050.html Mon, 26 Sep 2022 01:30:00 GMT 4faa3478-5f71-44d0-99ce-0422650772ec 2022-09-26T01:30:00Z Please beware of “spoofing e-mails, messages, etc.” that impersonate executives of Mitsubishi Tanabe Pharma Corporation (MTPC). https://www.tanabe-pharma.com/en/news/news20220805103086.html Fri, 05 Aug 2022 01:30:00 GMT 91893a30-97f5-4333-91d0-31904881a37a 2022-08-05T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20220803103029.html Wed, 03 Aug 2022 01:30:00 GMT 5a40f876-487b-4cf1-8b87-8e04a0c05235 2022-08-03T01:30:00Z Notice of Termination of the Recombinant Human Serum Albumin Business https://www.tanabe-pharma.com/en/news/news20220721103071.html Thu, 21 Jul 2022 01:30:00 GMT 7f0bdf3f-fcb1-4419-b4a3-8332ebe8c607 2022-07-21T01:30:00Z Humanitarian Donation to Ukraine https://www.tanabe-pharma.com/en/news/news20220713103068.html Wed, 13 Jul 2022 01:30:00 GMT dfb9e2af-c7ee-4b5e-8bb8-1380bcdb332d 2022-07-13T01:30:00Z Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation signed a sales collaboration agreement in Japan for GIP/GLP-1 receptor agonist “Tirzepatide” https://www.tanabe-pharma.com/en/news/news20220707103098.html Thu, 07 Jul 2022 01:30:00 GMT 730a5e59-ba46-4a89-9e3c-f6a2c4286c11 2022-07-07T01:30:00Z Anti-cytomegalovirus chemotherapeutic agents "Valixa® Dry Syrup 5000mg" Notification of application for additional indication of symptomatic congenital cytomegalovirus infection in Japan https://www.tanabe-pharma.com/en/news/news20220630103035.html Thu, 30 Jun 2022 01:30:00 GMT ec58b286-3dd2-46f2-84f6-569102c3654d 2022-06-30T01:30:00Z CANAGLU® Tablets 100mg Approved for the Indication of Chronic Kidney Disease Complicated with Type 2 Diabetes Mellitus in Japan https://www.tanabe-pharma.com/en/news/news20220621103061.html Tue, 21 Jun 2022 01:30:00 GMT 98ee1c11-ec18-4537-adb0-2bf111361512 2022-06-21T01:30:00Z RADICAVA ORS now available in U.S. for treatment of ALS https://www.tanabe-pharma.com/en/news/news20220616103072.html Thu, 16 Jun 2022 01:30:00 GMT 87b722d4-b20f-41d8-be57-b8f6f42c5bcd 2022-06-16T01:30:00Z Launch of DYSVAL® capsules 40mg for Treatment of Tardive Dyskinesia in Japan for the treatment of ALS https://www.tanabe-pharma.com/en/news/news20220601103060.html Wed, 01 Jun 2022 01:30:00 GMT bc6dfcd6-5298-42ae-899f-71824c73fb3b 2022-06-01T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20220513102955.html Fri, 13 May 2022 01:29:00 GMT a70dd3db-4391-4e4e-9cbe-3f61998ca7e4 2022-05-13T01:29:00Z New Japan-originated ALS treatment option available to patients in the U.S.―FDA approval of RADICAVA ORS® for the treatment of ALS https://www.tanabe-pharma.com/en/news/news20220513102822.html Fri, 13 May 2022 01:28:00 GMT 1c9dde95-e304-457c-b85e-14c550b9af17 2022-05-13T01:28:00Z Financial Information for FY2021 https://www.tanabe-pharma.com/en/news/news20220513001122.html Fri, 13 May 2022 01:28:00 GMT d04b6f47-0236-48eb-93e0-c493a1dd0025 2022-05-13T01:28:00Z Announcement of Organizational Changes and Personnel Changes of Mitsubishi Chemical Holdings Group https://www.tanabe-pharma.com/en/news/news20220427103051.html Wed, 27 Apr 2022 01:30:00 GMT 2a15ba9e-9acc-4c72-ab9e-4e1f3569ea85 2022-04-27T01:30:00Z Swissmedic has accepted the filling for a New Oral Edaravone Formulation for the treatment of ALS https://www.tanabe-pharma.com/en/news/news20220425103053.html Mon, 25 Apr 2022 01:30:00 GMT c22fa9bd-8128-4686-977f-e2d5358ef120 2022-04-25T01:30:00Z Marketing Authorization Application of Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine (BK1310/MT-2355) https://www.tanabe-pharma.com/en/news/news20220411103073.html Mon, 11 Apr 2022 01:30:00 GMT 4fd03d96-b7a2-4e7c-8256-19aecc75fc78 2022-04-11T01:30:00Z Long-Term Safety Profile from Phase 2b Clinical Trials of Parkinson's Disease Drug Candidate (ND0612) Presents at 2022 American Academy of Neurology Annual Meeting https://www.tanabe-pharma.com/en/news/news20220404103038.html Mon, 04 Apr 2022 01:30:00 GMT 969f22b5-fa8e-4ab1-a438-d55b0d93cc87 2022-04-04T01:30:00Z One Company, One Team https://www.tanabe-pharma.com/en/news/news20220401103055.html Fri, 01 Apr 2022 01:30:00 GMT 8e63ba61-8218-449a-aab2-30a1875883bd 2022-04-01T01:30:00Z Regulatory Approval of DYSVAL®capsules 40mg for Treatment of Tardive Dyskinesia in Japan https://www.tanabe-pharma.com/en/news/news20220328103032.html Mon, 28 Mar 2022 01:30:00 GMT 49412d40-a689-4795-8822-794c3a15a966 2022-03-28T01:30:00Z Submission of Oral Edaravone Formulation, MT-1186 New Drug Application in Japan for the Treatment of ALS https://www.tanabe-pharma.com/en/news/news20220314103054.html Mon, 14 Mar 2022 01:30:00 GMT efabf4a0-ab10-49a5-879a-5c71b477dcb9 2022-03-14T01:30:00Z Progress of Innovative Drug Discovery Research Collaboration with HitGen https://www.tanabe-pharma.com/en/news/news20220225103087.html Fri, 25 Feb 2022 01:30:00 GMT 7a83f712-47f1-4b43-b71d-7f935716c46e 2022-02-25T01:30:00Z COVID-19 vaccine, "COVIFENZ®"(MT-2766) has been approved in Canada. https://www.tanabe-pharma.com/en/news/news20220224103015.html Thu, 24 Feb 2022 01:30:00 GMT f41a41bf-b2ab-4b20-b40e-46b609231b79 2022-02-24T01:30:00Z Organizational Changes and Personnel Changes of Mitsubishi Chemical Holdings Group https://www.tanabe-pharma.com/en/news/news20220224102996.html Thu, 24 Feb 2022 01:29:00 GMT be19e567-45fd-4df2-9ea4-bee9560f4995 2022-02-24T01:29:00Z Financial Information for Q3 of FY2021 https://www.tanabe-pharma.com/en/news/news20220203019122.html Thu, 03 Feb 2022 01:30:00 GMT a1a85a9b-05fe-4231-8643-9e426a27fc3d 2022-02-03T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20220203102988.html Thu, 03 Feb 2022 01:29:00 GMT 701556ac-b1ac-491d-ae37-6d5618c5716e 2022-02-03T01:29:00Z Regulatory Approval of Cariprazine (MP-214) for Bipolar Disorder in Singapore https://www.tanabe-pharma.com/en/news/news20220202103057.html Wed, 02 Feb 2022 01:30:00 GMT 495b9a48-444c-4617-9295-ce7362be872b 2022-02-02T01:30:00Z Mitsubishi Tanabe Pharma Corporation Enters into Exclusive License Agreement with ADC Therapeutics to Develop and Commercialize Loncastuximab Tesirine, Anti-CD19 Antibody Drug Conjugate ("ADC"), for Cancer in Japan https://www.tanabe-pharma.com/en/news/news20220118103097.html Tue, 18 Jan 2022 01:30:00 GMT 2e9548ff-fd23-415a-95c5-9414daaab527 2022-01-18T01:30:00Z FDA Acceptance of New Drug Application for Oral Edaravone Formulation for the Treatment of ALS https://www.tanabe-pharma.com/en/news/news20220113103059.html Thu, 13 Jan 2022 01:30:00 GMT e7d0104d-2678-42a3-80c8-3007b035d1fa 2022-01-13T01:30:00Z Personnel Changes at Mitsubishi Chemical Holdings Group https://www.tanabe-pharma.com/en/news/news20220107103091.html Fri, 07 Jan 2022 01:30:00 GMT c245c32d-8f99-4d4b-9761-7cf03fce6b8e 2022-01-07T01:30:00Z Tianjin Tanabe and Suzuken (Shenzhen) join hands to promote TENELIA in China https://www.tanabe-pharma.com/en/news/news20211222103071.html Wed, 22 Dec 2021 01:30:00 GMT e8290b83-9e15-4b4d-ad86-e976f14b6575 2021-12-22T01:30:00Z MT-2766, the world's first plant-based COVID-19 vaccine candidate Application for approval was submitted in Canada. https://www.tanabe-pharma.com/en/news/news20211217103031.html Fri, 17 Dec 2021 01:30:00 GMT a4a272f6-0842-47a8-bca8-3821c24061ba 2021-12-17T01:30:00Z Global Phase 3 Safety Study Results of Investigational Oral Edaravone MT-1186 in the treatment of ALS https://www.tanabe-pharma.com/en/news/news20211210103080.html Fri, 10 Dec 2021 01:30:00 GMT 36cb2e09-623a-4ab4-9763-d7e851e62451 2021-12-10T01:30:00Z MT-2766, Adjuvanted COVID-19 Vaccine Candidate, Showed Positive Efficacy and Safety Results in Phase 3 Study Conducted in an Environment Dominated by the Variants https://www.tanabe-pharma.com/en/news/news20211207103031.html Tue, 07 Dec 2021 01:30:00 GMT 7910aa41-6f65-4e16-ac9f-de8d747ca603 2021-12-07T01:30:00Z Sustainability Information https://www.tanabe-pharma.com/en/news/news20211207102957.html Tue, 07 Dec 2021 01:29:00 GMT 26ca871f-5998-41f2-b4e3-5dda03c52bad 2021-12-07T01:29:00Z Co-promotion agreement for VMAT2 inhibitor MT-5199 in Japan with Janssen Pharmaceutical K.K. https://www.tanabe-pharma.com/en/news/news20211203103020.html Fri, 03 Dec 2021 01:30:00 GMT d29e88ea-b4de-4669-bacd-96b8cb1772cc 2021-12-03T01:30:00Z Financial Information for Q2 of FY2021 https://www.tanabe-pharma.com/en/news/news20211102019122.html Tue, 02 Nov 2021 01:30:00 GMT bc4bc28e-f41d-4792-b818-bb34cf454798 2021-11-02T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20211102102927.html Tue, 02 Nov 2021 01:29:00 GMT 5bb806f8-65de-4556-8a51-4043279708bb 2021-11-02T01:29:00Z Transfer of Urso API Manufacturing Business https://www.tanabe-pharma.com/en/news/news20211020103072.html Wed, 20 Oct 2021 01:30:00 GMT 40c00e6f-272f-4d02-844c-9535eac07f7e 2021-10-20T01:30:00Z Top-line data of J-KINECT Study, Phase 2/3 study in Japan of VMAT2 inhibitor MT-5199 in TD, presented at the 31st annual meeting of the Japanese Society of Clinical Neuropsychopharmacology https://www.tanabe-pharma.com/en/news/news20211008103060.html Fri, 08 Oct 2021 01:30:00 GMT c3c36f14-eae4-4bbf-af10-cd3d13597884 2021-10-08T01:30:00Z Start of a Japanese Clinical Study of MT-2766, Adjuvanted COVID-19 Vaccine Candidate https://www.tanabe-pharma.com/en/news/news20210930103067.html Thu, 30 Sep 2021 01:30:00 GMT 512dfa74-b45f-42b3-9987-c1ca8ba729b3 2021-09-30T01:30:00Z Phase 2 Trial of MT-3921 Initiated for Treatment of Spinal Cord Injury https://www.tanabe-pharma.com/en/news/news20210908103020.html Wed, 08 Sep 2021 01:30:00 GMT 3d717919-c866-41e4-bfb3-52100c182d88 2021-09-08T01:30:00Z Inebilizumab has been approved in South Korea for Neuromyelitis Optica Spectrum Disorder https://www.tanabe-pharma.com/en/news/news20210805103052.html Thu, 05 Aug 2021 01:30:00 GMT f5c14600-fe78-4b66-a965-23dae91b5d9d 2021-08-05T01:30:00Z Application for approval of CANAGLU® Tablets 100mg for the indication of chronic kidney disease with type 2 diabetes mellitus in Japan https://www.tanabe-pharma.com/en/news/news20210804103090.html Wed, 04 Aug 2021 01:30:00 GMT 8859bf1e-23dc-4a1f-a495-01d9c9acb9c9 2021-08-04T01:30:00Z Financial Information for Q1 of FY2021 https://www.tanabe-pharma.com/en/news/news20210804019122.html Wed, 04 Aug 2021 01:30:00 GMT 46c9bab0-e9a6-4923-830d-03d709566dd1 2021-08-04T01:30:00Z MT-3921 Granted FDA Fast Track Designation for Treatment of Spinal Cord Injury https://www.tanabe-pharma.com/en/news/news20210804102910.html Wed, 04 Aug 2021 01:29:00 GMT 688e3d75-6827-45fe-ac35-2eafc5e783cf 2021-08-04T01:29:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20210804102782.html Wed, 04 Aug 2021 01:27:00 GMT 009733b3-e50e-4a6a-9a94-c2ffcbe23c8b 2021-08-04T01:27:00Z Strengthen the Lineup of ALS Treatments in the U.S.EXSERVANTM (RILUZOLE) IS NOW AVAILABLE IN THE U.S. FOR THE TREATMENT OF ALS https://www.tanabe-pharma.com/en/news/news20210701103071.html Thu, 01 Jul 2021 01:30:00 GMT f0eb2407-9979-496f-a9a3-35972afdcfce 2021-07-01T01:30:00Z Launch of TENELIA® OD Tablet for Type 2 Diabetes Mellitus ―Toward further convenience and improvement of Medication Compliance of DPP-4 inhibitors https://www.tanabe-pharma.com/en/news/news20210618103049.html Fri, 18 Jun 2021 01:30:00 GMT 287f3144-526d-4d57-9456-a8e2e552a880 2021-06-18T01:30:00Z Launch of UPLIZNA® for I.V. Infusion 100mg as a new option for the treatment of Neuromyelitis Optica Spectrum Disorder in Japan https://www.tanabe-pharma.com/en/news/news20210601103045.html Tue, 01 Jun 2021 01:30:00 GMT b404734b-f4ba-4ecd-844c-1bb807c8bb72 2021-06-01T01:30:00Z Establishment of AI Technologies for Drug Screening To Accelerate Data-Driven Drug Discovery https://www.tanabe-pharma.com/en/news/news20210525103073.html Tue, 25 May 2021 01:30:00 GMT 6b317de8-847a-4216-ada4-e9bef6ae98dc 2021-05-25T01:30:00Z Initiatives Against COVID-19 in Canada - Achieved Positive Interim Phase 2 Results for adjuvanted COVID-19 vaccine candidate - https://www.tanabe-pharma.com/en/news/news20210519103056.html Wed, 19 May 2021 01:30:00 GMT 9cbbf2d8-3cd0-4c32-9e7a-a43ce2760c78 2021-05-19T01:30:00Z Discontinuation of the Development of Nucleic Acid Products "MT-5745 (STNM01)" for Ulcerative Colitis and an Impairment Loss (non-recurring item) https://www.tanabe-pharma.com/en/news/news20210512103040.html Wed, 12 May 2021 01:30:00 GMT 09f7e35e-7e27-4bfb-a44a-9ea7577d015f 2021-05-12T01:30:00Z Financial Information for FY2020 https://www.tanabe-pharma.com/en/news/news20210512019122.html Wed, 12 May 2021 01:30:00 GMT f628e10f-15e3-4107-9b41-c7acf4a39c30 2021-05-12T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20210512102885.html Wed, 12 May 2021 01:28:00 GMT cc3729d5-6bcf-46c7-b797-a4ff4103c64b 2021-05-12T01:28:00Z Initiatives Against COVID-19 in Canada - Health Canada Initiates the Review of the Rolling Submission for COVID-19 VLP Vaccine Candidate - https://www.tanabe-pharma.com/en/news/news20210426103079.html Mon, 26 Apr 2021 01:30:00 GMT 91e642d2-9abf-4cc1-b7d1-78052ae39f8f 2021-04-26T01:30:00Z Notification of Marketing Authorization Application of Valbenazine (MT-5199) for the Treatment of Tardive Dyskinesia in Japan https://www.tanabe-pharma.com/en/news/news20210422103087.html Thu, 22 Apr 2021 01:30:00 GMT e1bd1c3c-81d7-4dc5-b113-bc482fcad3f1 2021-04-22T01:30:00Z Mitsubishi Tanabe and Mineralys entered into the exclusive License Agreement for a cardiovascular agent “MT-4129” and FDA Accepts IND Application https://www.tanabe-pharma.com/en/news/news20210408103032.html Thu, 08 Apr 2021 01:30:00 GMT c4a6fa5e-947f-45a5-829b-a4214b9896f6 2021-04-08T01:30:00Z Phase -2 Clinical Trial of MT-7117 Initiated in the U.S., Canada, and Europe for the Rare Disease, Diffuse Cutaneous Systemic Sclerosis (dcSSc) https://www.tanabe-pharma.com/en/news/news20210331103030.html Wed, 31 Mar 2021 01:30:00 GMT e32ef10d-2e43-44c0-8e54-75eaf613ee31 2021-03-31T01:30:00Z Mitsubishi Tanabe Pharma Wins Patent Infringement Lawsuit of Canagliflozin Hydrate in the U.S. District Court https://www.tanabe-pharma.com/en/news/news20210331102930.html Wed, 31 Mar 2021 01:29:00 GMT 1350a41f-ffa1-4720-acd7-ea6750266ca9 2021-03-31T01:29:00Z The Global Health Innovative Technology Fund provides grant to Mitsubishi Tanabe Pharma and DNDi for Chagas disease and leishmaniasis drug discovery ～Targeting treatments for infectious diseases that impact people in developing countries～ https://www.tanabe-pharma.com/en/news/news20210331102862.html Wed, 31 Mar 2021 01:28:00 GMT 9faa7651-ba8f-4bc7-93c8-006956c523d0 2021-03-31T01:28:00Z Manufacturing and Marketing Approval of UPLIZNA® for I.V. Infusion 100mg for the Treatment of Neuromyelitis Optica Spectrum Disorder in Japan https://www.tanabe-pharma.com/en/news/news20210323103018.html Tue, 23 Mar 2021 01:30:00 GMT 8863f49c-da5f-415b-bb2b-511aa7636c08 2021-03-23T01:30:00Z Initiatives Against COVID-19 in Canada - Initiate Phase 3 Portion of Phase 2/3 Clinical Trials and Fast Track Designation Granted by FDA - https://www.tanabe-pharma.com/en/news/news20210317103051.html Wed, 17 Mar 2021 01:30:00 GMT 2c2b053d-2ef9-4659-9de0-db81f4bc81bc 2021-03-17T01:30:00Z Formulation of MISSION, VISION 30 and Medium-Term Management Plan 21–25 -Creating hope for all facing illness.- https://www.tanabe-pharma.com/en/news/e_MTPC210303.html Wed, 03 Mar 2021 01:30:00 GMT 305e6fa2-4cc9-455f-9a04-703f2ea61ac9 2021-03-03T01:30:00Z Establish NeuroDiscovery Lab in the Boston Area to Strengthen the Discovery of Drug Targets for the Central Nervous System Disorders https://www.tanabe-pharma.com/en/news/news20210303102931.html Wed, 03 Mar 2021 01:29:00 GMT ec88a0b4-1247-406d-a401-93a5fc263651 2021-03-03T01:29:00Z Canagliflozin (TA-7284) has been approved in Taiwan For Diabetic Nephropathy https://www.tanabe-pharma.com/en/news/news20210226103054.html Fri, 26 Feb 2021 01:30:00 GMT 6738c3cf-45a9-4081-8e34-a1b93401b4eb 2021-02-26T01:30:00Z Financial Information for Q2 of FY2020 https://www.tanabe-pharma.com/en/news/news20211104019122.html Wed, 03 Feb 2021 01:30:00 GMT 0cf2394e-e18e-43d6-9cd0-334a4ab2ef53 2021-02-03T01:30:00Z Results of J-KINECT Study,Phase 2/3 study in Japan of VMAT2 inhibitor MT-5199 in tardive dyskinesia https://www.tanabe-pharma.com/en/news/news20210203103095.html Wed, 03 Feb 2021 01:30:00 GMT 8e6f351d-828e-46f7-8ccc-724e934af2ad 2021-02-03T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20210203102887.html Wed, 03 Feb 2021 01:28:00 GMT e447b4bb-2274-48b9-ac5f-be7ec8c8ac3b 2021-02-03T01:28:00Z Mitsubishi Tanabe Pharma and Pharma Foods International Enter into an Exclusive Licensing Agreement for a New Therapeutic Antibody to treat Autoimmune Diseases https://www.tanabe-pharma.com/en/news/news20210126103050.html Tue, 26 Jan 2021 01:30:00 GMT a3becd9b-9fb3-4d39-ba10-ae72dada0ddf 2021-01-26T01:30:00Z Mitsubishi Tanabe Pharma and TAKEDA Share Internal Experimental Data to Accelerate Data-Driven Drug Discovery https://www.tanabe-pharma.com/en/news/news20210118103063.html Mon, 18 Jan 2021 01:30:00 GMT 6d3d8dcd-15be-4120-aa68-4e2027214d7b 2021-01-18T01:30:00Z Notice of the Arbitral Award on the License Agreement with Kolon Life Science https://www.tanabe-pharma.com/en/news/news20210114103056.html Thu, 14 Jan 2021 01:30:00 GMT 69150401-1dc2-47a4-8db1-b615a593f389 2021-01-14T01:30:00Z Initiatives Against COVID-19 in Canada - Initiate Phase 2/3 Clinical Trials of VLP Vaccine Candidate - https://www.tanabe-pharma.com/en/news/news20201116103075.html Mon, 16 Nov 2020 01:30:00 GMT 6e516f0f-ce79-4133-bb6f-45d7003ff352 2020-11-16T01:30:00Z Initiatives Against COVID-19 in Canada - Phase 1 Results for COVID-19 Vaccine Candidate - https://www.tanabe-pharma.com/en/news/news20201111103020.html Wed, 11 Nov 2020 01:30:00 GMT 49fbb083-5db3-4628-a9a3-89ef3fa8137d 2020-11-11T01:30:00Z Changes in Continuous Subcutaneous Liquid levodopa/carbidopa Administration (ND0612) for patients with fluctuating Parkinson’s disease Development Plan and an Impairment Loss (Non-recurring Items) https://www.tanabe-pharma.com/en/news/news20201104103053.html Wed, 04 Nov 2020 01:30:00 GMT 44fa3e69-7eaf-45be-bc63-081e57a2579e 2020-11-04T01:30:00Z Financial Information for Q1 of FY2020 https://www.tanabe-pharma.com/en/news/news20200804019122.html Wed, 04 Nov 2020 01:30:00 GMT ac861aca-7d77-488f-abc3-e5d42d63b69a 2020-11-04T01:30:00Z Pipeline ― State of New Product Development https://www.tanabe-pharma.com/en/news/news20201104102869.html Wed, 04 Nov 2020 01:28:00 GMT 93088254-5fe2-4e79-a669-21e3bc8a2b31 2020-11-04T01:28:00Z Sustainability Information https://www.tanabe-pharma.com/en/news/news20201026103099.html Mon, 26 Oct 2020 01:30:00 GMT ea8931d5-8fbb-4bfd-8b31-c34bdcf6cb8f 2020-10-26T01:30:00Z Initiatives Against COVID-19 in Canada - Reached Agreements with Government of Canada to Receive Development Funding and Supply VLP Vaccine - https://www.tanabe-pharma.com/en/news/news20201026102941.html Mon, 26 Oct 2020 01:29:00 GMT de502867-c458-415f-a59a-200938472313 2020-10-26T01:29:00Z Canagliflozin (TA-7284) has been approved in Indonesia for Type2 Diabetes Mellitus https://www.tanabe-pharma.com/en/news/news20201008103054.html Thu, 08 Oct 2020 01:30:00 GMT 9432b406-285a-495f-a816-bcdd732f77af 2020-10-08T01:30:00Z The website has been redesigned. https://www.tanabe-pharma.com/en/news/news20200827103015.html Thu, 27 Aug 2020 01:30:50 GMT 4615859e-e10f-4428-bf9e-5eacd39b785b 2020-08-27T01:30:50Z Launch of VAFSEO®, for the treatment of renal anemia (HIF-PH inhibitor) in Japan https://www.tanabe-pharma.com/en/news/news20200826103097.html Wed, 26 Aug 2020 01:30:00 GMT 69f07105-23c4-4c5a-b817-be5a97dc9973 2020-08-26T01:30:00Z Financial Information for Q3 of FY2020 https://www.tanabe-pharma.com/en/news/news20200203019122.html Tue, 04 Aug 2020 01:30:00 GMT 63058370-962f-4f00-a938-8657d68a98e3 2020-08-04T01:30:00Z Clinical Trial Information https://www.tanabe-pharma.com/en/news/news20200728103079.html Tue, 28 Jul 2020 01:30:00 GMT 1bade671-d6a1-4adb-aa86-c262acecf964 2020-07-28T01:30:00Z As the First ALS Treatment in Indonesia RADICAVA has been approved first in ASEAN countries https://www.tanabe-pharma.com/en/news/news20200716103092.html Thu, 16 Jul 2020 01:30:00 GMT 606d1472-5102-48b5-9b06-1e674bc38559 2020-07-16T01:30:00Z Initiatives Against COVID-19 in Canada - Initiated Phase 1 Clinical Trials of VLP Vaccine Candidate https://www.tanabe-pharma.com/en/news/news20200715103049.html Wed, 15 Jul 2020 01:30:00 GMT 077008c1-781e-410b-9a6e-ee8e79ad4928 2020-07-15T01:30:00Z Announcement of Collaboration between Medicago and GSK in the Development of COVID-19 Vaccine and the Start of Phase 1 Clinical Trials https://www.tanabe-pharma.com/en/news/news20200708103010.html Wed, 08 Jul 2020 01:30:00 GMT c22a20ce-8faa-4862-8b9b-ea26b5781398 2020-07-08T01:30:00Z Manufacturing and Marketing Approval of VAFSEO® Tablets (HIF-PH inhibitor, vadadustat) for renal anemia in Japan https://www.tanabe-pharma.com/en/news/news20200629103056.html Mon, 29 Jun 2020 01:30:00 GMT a9108fe3-719c-45d3-971a-689c027c8af8 2020-06-29T01:30:00Z Notification of Marketing Authorization Application for Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder in Japan https://www.tanabe-pharma.com/en/news/news20200626103086.html Fri, 26 Jun 2020 01:30:00 GMT e795f35d-36df-4901-bbd2-9d317a3af6d8 2020-06-26T01:30:00Z Start of a Phase 3 Clinical Trial of MT-7117 for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) https://www.tanabe-pharma.com/en/news/news20200615103081.html Mon, 15 Jun 2020 01:30:00 GMT a887d52a-31f4-498b-9af9-c6de004ec418 2020-06-15T01:30:00Z Regulatory Approval of Thailand for Marketing Teneligliptin (MP-513)， a treatment agent for type 2 diabetes mellitus https://www.tanabe-pharma.com/en/news/news20200525103081.html Mon, 25 May 2020 01:30:00 GMT f42f51b4-91c0-4b08-91cb-0e3d35c4a66a 2020-05-25T01:30:00Z Initiatives Against COVID-19 in Canada -Intermediary Results of VLP Vaccine Pre-clinical Study https://www.tanabe-pharma.com/en/news/news20200518102339.html Mon, 18 May 2020 01:31:00 GMT 3da761ca-24c1-4ed7-8d16-4a19905fb0b8 2020-05-18T01:31:00Z Co-marketing agreement concerning Vadadustat (MT-6548) for renal anemia in Japan with Fuso Pharmaceutical in hemodialysis and peritoneal dialysis patients https://www.tanabe-pharma.com/en/news/news20200518102940.html Mon, 18 May 2020 01:29:00 GMT 868928bf-5c0b-432e-a55e-c4738cd51181 2020-05-18T01:29:00Z Financial Information for FY2019 https://www.tanabe-pharma.com/en/news/news20200513019122.html Wed, 13 May 2020 01:30:00 GMT dcf16746-8b4a-4065-86ee-723f9c836c6b 2020-05-13T01:30:00Z Notification of Changes in the U.S. Development Plan of VLP Vaccine for Seasonal Influenza Prevention (MT-2271) and an Impairment Loss (Non-recurring Items) https://www.tanabe-pharma.com/en/news/news20200428103015.html Tue, 28 Apr 2020 01:30:00 GMT dd9b7851-056d-43d4-b7b4-beb72e87a138 2020-04-28T01:30:00Z SIMPONI® self-injection formulation for ulcerative colitis now reimbursed through NHI https://www.tanabe-pharma.com/en/news/news20200401103017.html Wed, 01 Apr 2020 01:30:00 GMT f3d8add6-e328-4f98-a1f8-5fb3175cf85c 2020-04-01T01:30:00Z STELARA® (ustekinumab) Now Approved for the Treatment of Adults with Moderate-to-Severe Ulcerative Colitis in Japan https://www.tanabe-pharma.com/en/news/news20200325103086.html Wed, 25 Mar 2020 01:30:00 GMT a098111c-9cc6-45dd-9e53-76c147de8a79 2020-03-25T01:30:00Z Medicago, a subsidiary in Canada, is tackling with COVID-19, coronavirus https://www.tanabe-pharma.com/en/news/news20200312103081.html Thu, 12 Mar 2020 01:30:00 GMT b83281e7-f67b-415f-ae44-4e897aee1eb1 2020-03-12T01:30:00Z Announcement Concerning Delisting of the Company Shares https://www.tanabe-pharma.com/en/news/news20200226103022.html Wed, 26 Feb 2020 01:30:00 GMT bd8bb6ff-ad8f-40a4-890f-9870072640eb 2020-02-26T01:30:00Z Change in Representative Director https://www.tanabe-pharma.com/en/news/MTPC200225.html Tue, 25 Feb 2020 01:30:00 GMT 8eb00efd-60b3-4895-8d1e-bb0a6f3d0ebc 2020-02-25T01:30:00Z Mitsubishi Tanabe Pharma expands domestic co-promotion framework for STELARA®. An application for an additional indication has been filed for ulcerative colitis, which will be included in co-promotion activities. https://www.tanabe-pharma.com/en/news/news20200205103026.html Wed, 05 Feb 2020 01:30:00 GMT 2f6de19f-d407-43bd-9032-b4636ec0bcec 2020-02-05T01:30:00Z Announcement of Mitsubishi Chemical Holdings Corporation’s Decision to Make a Demand for Sale of Our Shares, and Our Approval of that Demand for Sale of Our Shares and Delisting of Our Shares https://www.tanabe-pharma.com/en/news/news20200117103033.html Fri, 17 Jan 2020 01:30:00 GMT 0dfc4c63-cf5e-4167-a7aa-0711f689b2d4 2020-01-17T01:30:00Z Change in Representative Director https://www.tanabe-pharma.com/en/news/MTPC200114_3.html Tue, 14 Jan 2020 01:30:00 GMT 30a8903f-cb56-4687-b949-fd1a324d0387 2020-01-14T01:30:00Z Announcement Concerning Results of the Tender Offer of Our Shares by Mitsubishi Chemical Holdings Corporation which is Our Controlling Shareholder https://www.tanabe-pharma.com/en/news/news20200108103082.html Wed, 08 Jan 2020 01:30:00 GMT 059df158-9d4b-4f84-8695-454aee9f6521 2020-01-08T01:30:00Z Launch of Alesion® LX Ophthalmic Solution 0.1% in Japan https://www.tanabe-pharma.com/en/news/news20191127103011.html Wed, 27 Nov 2019 01:30:00 GMT d49bbdaf-a9af-4b10-9353-614a8faaf221 2019-11-27T01:30:00Z Mitsubishi Tanabe Pharma Announces the Start of a Phase 3 Clinical Trial using Oral Suspension of Edaravone for ALS https://www.tanabe-pharma.com/en/news/news20191125103074.html Mon, 25 Nov 2019 01:30:00 GMT a25c749c-db9a-47d4-aeb3-020609add820 2019-11-25T01:30:00Z Announcement of Mitsubishi Tanabe Pharma Corporation’s Opinion RegardingTender Offer for Shares in Mitsubishi Tanabe Pharma Corporation by the Controlling Shareholder Mitsubishi Chemical Holdings Corporation, and Recommendation to Tender Shares https://www.tanabe-pharma.com/en/news/news20191118103043.html Mon, 18 Nov 2019 01:30:00 GMT 47c0389a-1e44-46a2-b494-769fba1cf4df 2019-11-18T01:30:00Z To Our Shareholders: Notice of Statement of Opinion Regarding Tender Offer for Mitsubishi Tanabe’s Shares by Mitsubishi Chemical Holdings Corporation, and Recommendation to Tender Shares https://www.tanabe-pharma.com/en/news/news20191118102936.html Mon, 18 Nov 2019 01:29:00 GMT 8e41a4f7-db84-4b10-9eae-3fd2210700c8 2019-11-18T01:29:00Z Mitsubishi Tanabe Pharma Corporation Announces Results of the MT-7117 ENDEAVOR Study for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP) https://www.tanabe-pharma.com/en/news/news20191111103028.html Mon, 11 Nov 2019 01:30:00 GMT 870e6ed8-4870-454c-b3d3-79256513af5e 2019-11-11T01:30:00Z HIF-PH Inhibitor Vadadustat (MT-6548) Japan Phase 3 results for the treatment of renal anemia at American Society of Nephrology, Kidney Week 2019 https://www.tanabe-pharma.com/en/news/news20191111102997.html Mon, 11 Nov 2019 01:29:00 GMT ec736faf-7d58-41f2-bf29-8b7c0ab142d9 2019-11-11T01:29:00Z Revision to the First Half Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2020 https://www.tanabe-pharma.com/en/news/news20191025103089.html Fri, 25 Oct 2019 01:30:00 GMT 4345192b-3768-474c-9271-31f9efc72058 2019-10-25T01:30:00Z Vadadustat (MT-6548) Japan Phase 3 results for treatment of renal anemia to be presented at ASN Kidney Week 2019 https://www.tanabe-pharma.com/en/news/news20191025102926.html Fri, 25 Oct 2019 01:29:00 GMT 560479a6-b757-47e7-b812-fc911295b04f 2019-10-25T01:29:00Z Mitsubishi Tanabe Pharma enters into a licensing agreement with Viela Bio for inebilizumab, a treatment agent for neuromyelitis optica spectrum disorder, in Japan and other Asian regions https://www.tanabe-pharma.com/en/news/news20191009103064.html Wed, 09 Oct 2019 01:30:00 GMT 7cba2c33-1f5e-4f74-a236-815fd1c99678 2019-10-09T01:30:00Z Notification of acceptance of the New Drug Submission for Scientific Review of VLP Seasonal Influenza Vaccines（MT-2271）by Health Canada https://www.tanabe-pharma.com/en/news/news20191002103023.html Wed, 02 Oct 2019 01:30:00 GMT ce9f5193-f854-47b4-a358-a9b000eb6378 2019-10-02T01:30:00Z Mitsubishi Tanabe Pharma to participate in new screening program through the Global Health Innovative Technology Fund ～Targeting treatments for infectious diseases that burden the developing countries～ https://www.tanabe-pharma.com/en/news/news20190930103082.html Mon, 30 Sep 2019 01:30:00 GMT a587b332-518e-4066-8ea6-6dee2905fc64 2019-09-30T01:30:00Z NMPA accepts our filing for TENELIA, a treatment agent for type 2 diabetes mellitus in China https://www.tanabe-pharma.com/en/news/news20190924103023.html Tue, 24 Sep 2019 01:30:00 GMT a1b4e12c-66ed-4a31-8375-1ce6258690ab 2019-09-24T01:30:00Z Notice Regarding the Conclusion of Joint Sales Promotion Contract Concerning Alesion® Ophthalmic Solution 0.05% and Alesion® LX Ophthalmic Solution 0.1% between Mitsubishi Tanabe Pharma and Santen Pharmaceutical Co.; Ltd. https://www.tanabe-pharma.com/en/news/news20190920103098.html Fri, 20 Sep 2019 01:30:00 GMT 5e2fa879-eca9-46d6-b471-ad0e3f3b6fbd 2019-09-20T01:30:00Z Mitsubishi Tanabe Pharma Included in the Dow Jones Sustainability Asia Pacific Index https://www.tanabe-pharma.com/en/news/news20190918103031.html Wed, 18 Sep 2019 01:30:00 GMT 13f7b13b-61fd-404e-a2ca-d7c7d47d04d1 2019-09-18T01:30:00Z Mitsubishi Tanabe Pharma and Daiichi Sankyo announce alliance for ALS treatment agent edaravone in Brazil https://www.tanabe-pharma.com/en/news/news20190917103099.html Tue, 17 Sep 2019 01:30:00 GMT 007b9098-d73c-4512-a9eb-53f4273802dc 2019-09-17T01:30:00Z Notice regarding the launch of Collategene® intramuscular injection 4 mg, an HGF gene therapy product https://www.tanabe-pharma.com/en/news/news20190904103057.html Wed, 04 Sep 2019 01:30:00 GMT 4ebccc7f-5d7f-4231-a161-26eddee1c7fa 2019-09-04T01:30:00Z The Start of a Phase 3 Clinical Trial of Continuous Subcutaneous Liquid levodopa/carbidopa Administration (ND0612) for patients with fluctuating Parkinson’s disease https://www.tanabe-pharma.com/en/news/news20190828103042.html Wed, 28 Aug 2019 01:30:00 GMT 26ad39b7-947c-4a4e-b664-d2694da65027 2019-08-28T01:30:00Z PhaseⅠClinical Trial study protocol for MT-3921 in Patients with Spinal Cord Injury submitted to the US IND https://www.tanabe-pharma.com/en/news/news20190808103090.html Thu, 08 Aug 2019 01:30:00 GMT 544212d6-3f30-445b-a67c-025ae7cb3e94 2019-08-08T01:30:00Z Regulatory Approval for Marketing Cariprazine (MP-214) for the Treatment of Schizophrenia in Part of the ASEAN (Singapore and Thailand) https://www.tanabe-pharma.com/en/news/news20190808102968.html Thu, 08 Aug 2019 01:29:00 GMT 5882d3a3-40e9-45fb-a57a-11929374465a 2019-08-08T01:29:00Z NMPA approved Japan-originated ALS treatment Edaravone in China https://www.tanabe-pharma.com/en/news/news20190807103094.html Wed, 07 Aug 2019 01:30:00 GMT d60413e1-f559-4757-8a52-c9b473985702 2019-08-07T01:30:00Z Commencement of R&D of Gene Therapy Product for Hemophilia B https://www.tanabe-pharma.com/en/news/news20190806103094.html Tue, 06 Aug 2019 01:30:00 GMT 91244783-8315-4d3c-a24f-24c9d4824c96 2019-08-06T01:30:00Z Submission of Vadadustat (MT-6548) New Drug Application in Japan for renal anemia https://www.tanabe-pharma.com/en/news/news20190723103089.html Tue, 23 Jul 2019 01:30:00 GMT 622633c6-d0f3-4b71-9978-23135ca2f9e8 2019-07-23T01:30:00Z Withdrawal of Marketing Authorization Application of edaravone for ALS in the European Union https://www.tanabe-pharma.com/en/news/news20190530103068.html Thu, 30 May 2019 01:30:00 GMT 5a5b50bd-f15d-4476-8a49-fa818027a0a2 2019-05-30T01:30:00Z Launch of SIMPONI® Subcutaneous Injection 50mg Autoinjector https://www.tanabe-pharma.com/en/news/news20190529103065.html Wed, 29 May 2019 01:30:00 GMT 7d2a4b00-1b28-4c3e-bc92-a7761f1f1b22 2019-05-29T01:30:00Z Mitsubishi Tanabe Pharma and Salix enter into a licensing agreement for MT-1303, a therapeutic agent for autoimmune diseases https://www.tanabe-pharma.com/en/news/news20190426103067.html Fri, 26 Apr 2019 01:30:00 GMT 00bf7796-0fb4-4a33-8856-05ebcb16a71e 2019-04-26T01:30:00Z Medicago Awarded "Best New Vaccine Technology/Platform" at the World Vaccine Congress https://www.tanabe-pharma.com/en/news/news20190426102939.html Fri, 26 Apr 2019 01:29:00 GMT 294d9c70-df91-4804-bbfd-3564ad0e2906 2019-04-26T01:29:00Z Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019 https://www.tanabe-pharma.com/en/news/news20190424103063.html Wed, 24 Apr 2019 01:30:00 GMT f3478a4f-b536-439f-83cc-a628937447a9 2019-04-24T01:30:00Z For the ALS patients in the world, we hope to deliver Japan-originated ALS treatment―NMPA accepts our filing for Radicut to treat ALS in China https://www.tanabe-pharma.com/en/news/news20190415103096.html Mon, 15 Apr 2019 01:30:00 GMT 387687e3-262b-4062-a49c-65787c79a711 2019-04-15T01:30:00Z Notice Regarding Reorganization of Research, Production, and Technology Bases https://www.tanabe-pharma.com/en/news/news20190411103016.html Thu, 11 Apr 2019 01:30:00 GMT 7591153f-16bc-4488-9b43-ce37f75062f1 2019-04-11T01:30:00Z The Global Health Innovative Technology Fund provides grant for joint research into anti-malarial drugs conducted by Mitsubishi Tanabe Pharma and a malaria research institution https://www.tanabe-pharma.com/en/news/news20190328103027.html Thu, 28 Mar 2019 01:30:00 GMT 7a20d2e1-f6ee-41ee-92e8-22ab3ce7efce 2019-03-28T01:30:00Z AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb Ischemia https://www.tanabe-pharma.com/en/news/news20190326103025.html Tue, 26 Mar 2019 01:30:00 GMT cebf264c-43d4-4305-b04c-10e7193f6b83 2019-03-26T01:30:00Z Aiming to expand our sales and to strengthen our business foundations in the growing ASEAN market Establishment of sales subsidiary in Malaysia and Vietnam Representative Office https://www.tanabe-pharma.com/en/news/news20190320103074.html Wed, 20 Mar 2019 01:30:00 GMT 0ea8f9d3-1823-41f0-8cb7-6cc0c77e3ac9 2019-03-20T01:30:00Z Topline Results of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Anemia due to CKD https://www.tanabe-pharma.com/en/news/news20190312103066.html Tue, 12 Mar 2019 01:30:00 GMT 5c29015c-d3b3-403c-b7bf-f6069249c939 2019-03-12T01:30:00Z Tianjin Tanabe and Servier Tianjin join hands to promote TENELIA® in China https://www.tanabe-pharma.com/en/news/news20190228103068.html Thu, 28 Feb 2019 01:30:00 GMT 6fc8c17b-d15b-4dd9-8f5d-265d03404a24 2019-02-28T01:30:00Z Mitsubishi Tanabe Pharma Received Notice of Request for Arbitration https://www.tanabe-pharma.com/en/news/news20190220103086.html Wed, 20 Feb 2019 01:30:00 GMT 016cc438-05e5-4479-adbe-e31a42a37531 2019-02-20T01:30:00Z FDA accepted an Investigational New Drug Application for MT-8633, an ADC Targeting cMet Positive Solid Tumors https://www.tanabe-pharma.com/en/news/news20190214103067.html Thu, 14 Feb 2019 01:30:00 GMT 9e20aa58-3724-4785-bea0-f2328048ff48 2019-02-14T01:30:00Z First Initiative in Digital Medicine Notice Regarding the Start of a Demonstration Project for TOMOCO, a Diabetes Care App https://www.tanabe-pharma.com/en/news/news20190212103019.html Tue, 12 Feb 2019 01:30:00 GMT 31296d34-c076-4a47-8c55-de2eaee305b4 2019-02-12T01:30:00Z Swissmedic approves RADICAVA, Japan-originated ALS treatment https://www.tanabe-pharma.com/en/news/news20190206103024.html Wed, 06 Feb 2019 01:30:00 GMT 80ca4aba-3e35-48c2-a7bb-2d91531fe536 2019-02-06T01:30:00Z Notice Regarding Conclusion of Stock Transfer Agreement for Tanabe Seiyaku Yoshiki Factory Co., Ltd. https://www.tanabe-pharma.com/en/news/news20190204103019.html Mon, 04 Feb 2019 01:30:00 GMT 0abc0c06-f1f5-404b-a86e-8b6f2a306a84 2019-02-04T01:30:00Z HitGen and Mitsubishi Tanabe Pharma Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration https://www.tanabe-pharma.com/en/news/news20181211103067.html Tue, 11 Dec 2018 01:30:00 GMT e1b17cef-ed4d-48fa-918a-e047c8a948a6 2018-12-11T01:30:00Z Conduct a study to identify and measure specific biomarkers in ALS - we will strive to deliver a beneficial therapy option to patients - https://www.tanabe-pharma.com/en/news/news20181210103049.html Mon, 10 Dec 2018 01:30:00 GMT 00ab7a61-5bc5-4c6c-b613-c16b9c3cbac8 2018-12-10T01:30:00Z Notice Regarding Revision of Medium-Term Management Plan 16-20: Open Up the Future https://www.tanabe-pharma.com/en/news/news20181119103044.html Mon, 19 Nov 2018 01:30:00 GMT e0ddff3a-ed8d-475b-b7b2-f22525fb1107 2018-11-19T01:30:00Z Mitsubishi Tanabe Pharma to present New data on Investigational Oral Suspension of Edaravone for ALS at 29th International Symposium on ALS/MND https://www.tanabe-pharma.com/en/news/news20181115103066.html Thu, 15 Nov 2018 01:30:00 GMT cd447c89-aad1-41a6-8f0c-3dc636b55737 2018-11-15T01:30:00Z Strategic Research Collaboration for the Development of Innovative Antibody Drug to Treat Autoimmune Diseases https://www.tanabe-pharma.com/en/news/news20181022103058.html Mon, 22 Oct 2018 01:30:00 GMT 3bb3e3d4-03ad-4af8-ad0a-a8491b8d0303 2018-10-22T01:30:00Z Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Announce Second Public Recruitment Offering of "JOINUS®", a Joint Research Program to Discover New Drugs using Drug-Repositioning Compound Library https://www.tanabe-pharma.com/en/news/news20181009103028.html Tue, 09 Oct 2018 01:30:00 GMT 52226d6a-b462-42a8-b46d-f7881026d2f3 2018-10-09T01:30:00Z For the ALS patients in Canada, we hope to deliver Japan-originated ALS treatment ―Health Canada approves RADICAVA™ (edaravone) for the treatment of ALS https://www.tanabe-pharma.com/en/news/news20181005103035.html Fri, 05 Oct 2018 01:30:00 GMT 108f7ec4-4fca-4d5e-9f23-4ab9498f7abd 2018-10-05T01:30:00Z Company name changes of our oversea subsidiaries https://www.tanabe-pharma.com/en/news/news20180926103097.html Wed, 26 Sep 2018 01:30:00 GMT cd941a3e-83a8-4708-8561-0f649fd84126 2018-09-26T01:30:00Z Mitsubishi Tanabe Pharma Included in the Dow Jones Sustainability Asia Pacific Index https://www.tanabe-pharma.com/en/news/news20180918103052.html Tue, 18 Sep 2018 01:30:00 GMT cf2fa7c1-6bfe-49f1-a173-3a7009feb1c7 2018-09-18T01:30:00Z Mitsubishi Tanabe Pharma's MT-7117 Receives U.S. FDA Fast Track Designation for the Investigational Treatment of Patients with the Ultra-Rare Disease, Erythropoietic Protoporphyria https://www.tanabe-pharma.com/en/news/news20180727103055.html Fri, 27 Jul 2018 01:30:00 GMT bfe13aad-b433-42b6-b914-35d17e987ce8 2018-07-27T01:30:00Z Mitsubishi Tanabe Pharma Receives The 43rd (FY2018) Inoue Harushige Prize ― A challenge for the new drug against amyotrophic lateral sclerosis (ALS), research and development of edaravone― https://www.tanabe-pharma.com/en/news/news20180719103065.html Thu, 19 Jul 2018 01:30:00 GMT cbd49e50-79c4-48e5-b9ee-49940ac2a099 2018-07-19T01:30:00Z Mitsubishi Tanabe Pharma and Osaka University co-found the “Department of Neuro-Medical Science” - Toward the Innovative Drug Discovery for refractory Neurological Diseases - https://www.tanabe-pharma.com/en/news/news20180702103019.html Mon, 02 Jul 2018 01:30:00 GMT 8be1c2f7-6f3b-48a7-8940-608c5e7c4cfa 2018-07-02T01:30:00Z Open Call for Applicants for Researcher-Initiated Clinical Research Funds - We Ensure Transparency and Support Investigator-Initiated Research Based on Japan's Clinical Research Act - https://www.tanabe-pharma.com/en/news/news20180702102950.html Mon, 02 Jul 2018 01:29:00 GMT c201a7f3-e2b1-49b6-ad35-ed16916bbd22 2018-07-02T01:29:00Z Mitsubishi Tanabe Pharma and Janssen Pharmaceutical　K.K. update co-promotion framework for STELARA®, an anti-IL-12/23p40 monoclonal antibody Distribution will be transferred to Mitsubishi Tanabe Pharma, while the two companies will continue co-promotion of STELARA® to treat adults with Crohn’s disease in Japan https://www.tanabe-pharma.com/en/news/news20180628103021.html Thu, 28 Jun 2018 01:30:00 GMT 8567010f-02d3-4008-8d87-78adeb0805dc 2018-06-28T01:30:00Z TFDA approves Clenafin/Jublia for the treatment of Onychomycosis in Taiwan https://www.tanabe-pharma.com/en/news/news20180614103025.html Thu, 14 Jun 2018 01:30:00 GMT 6ded2783-048a-4d5f-930e-8c595e705b2a 2018-06-14T01:30:00Z Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development―Start of collaborative/competitive drug discovery research by three academic institutions and three pharmaceutical companies https://www.tanabe-pharma.com/en/news/news20180530103048.html Wed, 30 May 2018 01:30:00 GMT a4004fbb-1628-4cdd-aadc-94bd8e1681a3 2018-05-30T01:30:00Z For the ALS patients in the world, we hope to deliver Japan-originated ALS treatment―EMA accepts our filing for Edaravone to treat ALS https://www.tanabe-pharma.com/en/news/news20180528103048.html Mon, 28 May 2018 01:30:00 GMT 721b75ef-ef65-47f2-94b5-2ff5ed99c1d5 2018-05-28T01:30:00Z Canagliflozin (Antidiabetic agent) wins The Technology Award Grand Prize from the Japan Chemical Industry Association (JCIA) https://www.tanabe-pharma.com/en/news/news20180518103090.html Fri, 18 May 2018 01:30:00 GMT caea5985-6509-4cec-8aaf-2b2b53aa5bac 2018-05-18T01:30:00Z Update of Previous Disclosure ― Announcement of Filing a Request for Arbitration on the Licensing Agreement with Kolon Life Science https://www.tanabe-pharma.com/en/news/news20180410103069.html Tue, 10 Apr 2018 01:30:00 GMT 84398a48-dcd7-4004-a465-0237c6eb2937 2018-04-10T01:30:00Z To ALS patients in the world, we hope to deliver Japan-originated ALS treatment―Health Canada accepts our filing for Edaravone to treat ALS and we established commercializing company in Canada https://www.tanabe-pharma.com/en/news/news20180410102916.html Tue, 10 Apr 2018 01:29:00 GMT b2351305-7b20-432a-975a-5ac76c1140e7 2018-04-10T01:29:00Z Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug Development https://www.tanabe-pharma.com/en/news/news20180326103055.html Mon, 26 Mar 2018 01:30:00 GMT bf246d3b-d439-46cd-95f6-c1e442298d36 2018-03-26T01:30:00Z Name Change of our Singapore Subsidiary https://www.tanabe-pharma.com/en/news/news20180306103091.html Tue, 06 Mar 2018 01:30:00 GMT 451c2e92-5b2b-4889-b7b1-fec2937c55a9 2018-03-06T01:30:00Z Mitsubishi Tanabe Pharma Group started marketing CANAGLU® Tablets 100mg, a treatment agent for type 2 diabetes mellitus in Taiwan https://www.tanabe-pharma.com/en/news/news20180301103044.html Thu, 01 Mar 2018 01:30:00 GMT 6bb23872-7885-41f0-b7a1-145dda8eb4aa 2018-03-01T01:30:00Z Valixa® Tablet 450mg ―Public knowledge-based application for an additional pediatric indication for the prevention of CMV disease in organ transplant patients as well as application for an additional dosage form of dry syrup https://www.tanabe-pharma.com/en/news/news20180228103086.html Wed, 28 Feb 2018 01:30:00 GMT a6abe36f-9263-48c3-a421-1eb0446e115e 2018-02-28T01:30:00Z Swissmedic accepts our filing for Edaravone to treat ALS ― To ALS patients in the world, we hope to deliver Japan-originated ALS treatment https://www.tanabe-pharma.com/en/news/news20180123103019.html Tue, 23 Jan 2018 01:30:00 GMT 1ef25833-908b-4915-83b4-58c152188cc5 2018-01-23T01:30:00Z Approval in China Received for Additional Novastan® Indication for Acute Cerebral Infarction ― Reinforcing Our Pharmaceutical Development and Sales in China, the World's Second Largest Pharmaceutical Market https://www.tanabe-pharma.com/en/news/news20180116103094.html Tue, 16 Jan 2018 01:30:00 GMT 96cc9e10-a9d3-4503-9106-3630356a64ae 2018-01-16T01:30:00Z Launch of "KREMEZIN® Tablets 500mg" (Additional Formulation), Drug for Chronic Renal Failure ― For Improving Patients' Usage Experience and Medication Adherence ― https://www.tanabe-pharma.com/en/news/news20180111103095.html Thu, 11 Jan 2018 01:30:00 GMT 1d44f7b6-9c6d-49eb-ab2a-a8be09fae45f 2018-01-11T01:30:00Z Update of Previous Disclosure ― License Agreement with Kolon Life Science on Invossa® https://www.tanabe-pharma.com/en/news/news20171220103024.html Wed, 20 Dec 2017 01:30:00 GMT 753b0177-a794-458d-a59e-f6fc60060061 2017-12-20T01:30:00Z Strategic Collaboration for the Development of the Antibody Drug to Treat Neurodegenerative Diseases including ALS https://www.tanabe-pharma.com/en/news/news20171213103068.html Wed, 13 Dec 2017 01:30:00 GMT 77a39e73-311f-4ee5-8afd-af1d8a6302f8 2017-12-13T01:30:00Z Launch of Rupafin® tablets in Japan ―Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action) https://www.tanabe-pharma.com/en/news/news20171122103044.html Wed, 22 Nov 2017 01:30:00 GMT ee804d34-025b-46a8-baad-82d60be5f747 2017-11-22T01:30:00Z Distribution Agreement for Clenafin/Jublia in Taiwan https://www.tanabe-pharma.com/en/news/news20171108103034.html Wed, 08 Nov 2017 01:30:00 GMT 956721f1-9b8a-4999-9c29-096aa2c19c0d 2017-11-08T01:30:00Z Notice Regarding Mitsubishi Tanabe Pharma’s Acquisition of Stelic Institute & Co., Inc. Securing Nucleic Acid Pharmaceuticals of Inflammatory bowel disease for Future Launch in the U.S. https://www.tanabe-pharma.com/en/news/news20171101103050.html Wed, 01 Nov 2017 01:30:00 GMT 5a4e5688-d5b7-4bbb-9ef5-34691784de8c 2017-11-01T01:30:00Z Notice of the Start of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Renal Anemia https://www.tanabe-pharma.com/en/news/news20171101102993.html Wed, 01 Nov 2017 01:29:00 GMT 7d0fde71-a571-4119-a647-93cbf24ce591 2017-11-01T01:29:00Z Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2018 https://www.tanabe-pharma.com/en/news/news20171024103011.html Tue, 24 Oct 2017 01:30:00 GMT 29115484-138d-4cba-a36b-f8bae6bfb7a6 2017-10-24T01:30:00Z Completion of Acquisition of NeuroDerm (100% Ownership) https://www.tanabe-pharma.com/en/news/news20171018103088.html Wed, 18 Oct 2017 01:30:00 GMT 4faa937f-6ab8-49fd-b512-355ea3883862 2017-10-18T01:30:00Z Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library -Three Japanese pharmaceutical companies collaborate in facilitating drug discovery in Japan through open innov https://www.tanabe-pharma.com/en/news/news20171011103091.html Wed, 11 Oct 2017 01:30:00 GMT d43064bb-4abf-4d58-a368-ce2bf32770ed 2017-10-11T01:30:00Z Completion of Transfer of Shares of Generic Drugs Subsidiary (Update of Previous Disclosure) https://www.tanabe-pharma.com/en/news/news20171002103033.html Mon, 02 Oct 2017 01:30:00 GMT 27c9c1de-956e-4298-9e9a-95ec76841624 2017-10-02T01:30:00Z Organizational Change and Personnel Change https://www.tanabe-pharma.com/en/news/MTPC170929.html Fri, 29 Sep 2017 01:30:00 GMT 0f6f25b9-d18a-4fe9-acd4-ac25145e9095 2017-09-29T01:30:00Z Notice regarding acquisition of manufacturing and sales approval for Rupafin® tablets Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action) https://www.tanabe-pharma.com/en/news/news20170927103077.html Wed, 27 Sep 2017 01:30:00 GMT cdefbe93-df39-41b5-b21a-b6f03450648a 2017-09-27T01:30:00Z Notice of the Start of Phase 3 Clinical Study of VLP Seasonal Influenza Vaccine https://www.tanabe-pharma.com/en/news/news20170927102983.html Wed, 27 Sep 2017 01:29:00 GMT 5a10d052-b04b-4708-b9ab-b508eacfb5a1 2017-09-27T01:29:00Z Approval of Mitsubishi Tanabe Pharma’s Acquisition of NeuroDerm at NeuroDerm’s General Meeting of Shareholders https://www.tanabe-pharma.com/en/news/news20170913103054.html Wed, 13 Sep 2017 01:30:00 GMT ac3b9a81-2b69-4976-8ab5-33867c9d3588 2017-09-13T01:30:00Z Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug Launch of CANALIA® Combination Tablets, a type 2 diabetes mellitus treatment agent-Combination of selective DPP-4 inhibitor TENELIA® Tablets and SGLT2 inhibitor CANAGLU® Tablets- https://www.tanabe-pharma.com/en/news/news20170907103036.html Thu, 07 Sep 2017 01:30:00 GMT 1b49c657-283d-4966-8c08-26aefe57227f 2017-09-07T01:30:00Z Start of Operations of Vaccine Manufacturing Joint Venture: BIKEN Co., Ltd. https://www.tanabe-pharma.com/en/news/news20170904103037.html Mon, 04 Sep 2017 01:30:00 GMT e75a2632-b565-49b8-848e-a940f3d228be 2017-09-04T01:30:00Z Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis https://www.tanabe-pharma.com/en/news/news20170817103291.html Thu, 17 Aug 2017 01:30:00 GMT eb558960-85a1-4121-947b-a315c06de61b 2017-08-17T01:30:00Z RADICAVA to treat ALS now available in U.S. https://www.tanabe-pharma.com/en/news/news20170809103059.html Wed, 09 Aug 2017 01:30:00 GMT 747e5e89-74ef-4610-95ee-24a1ee4f7151 2017-08-09T01:30:00Z Notice regarding the initiation of a phase 2/3 clinical trial in Japan for tardive dyskinesia patients for VMAT2 inhibitor MT-5199 https://www.tanabe-pharma.com/en/news/news20170727103015.html Thu, 27 Jul 2017 01:30:00 GMT 9ff3e210-91cb-45dc-8320-9572d7382693 2017-07-27T01:30:00Z Mitsubishi Tanabe Pharma to Acquire NeuroDerm Ltd. https://www.tanabe-pharma.com/en/news/news20170724103031.html Mon, 24 Jul 2017 01:30:00 GMT 54302e14-7760-4567-89b4-72a756deec3b 2017-07-24T01:30:00Z Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug ―Application approved in Japan for CANALIA® Combination Tablets, a type 2 diabetes mellitus treatment agent -Combination of selective DPP-4 inhibitor TENELIA® Tablets and SGLT2 inhibitor CANAGLU® Tablets- https://www.tanabe-pharma.com/en/news/news20170703103028.html Mon, 03 Jul 2017 01:30:00 GMT 20b3b9fd-492b-46aa-b1d0-7fb7264af707 2017-07-03T01:30:00Z Conclusion of Agreement on Absorption-Type Company Split of Generic Drugs and Part of the Long-Listed Products Business https://www.tanabe-pharma.com/en/news/news20170630103011.html Fri, 30 Jun 2017 01:30:00 GMT 561d57b3-ee89-42f6-b70c-d6b4fddd0ce6 2017-06-30T01:30:00Z Fingolimod Hydrochloride wins Patent Infringement Lawsuit in the U.S. District Court https://www.tanabe-pharma.com/en/news/news20170620103057.html Tue, 20 Jun 2017 01:30:00 GMT 7af9dbf5-7883-4e7a-8ddb-1fa74bcf526f 2017-06-20T01:30:00Z Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund’s second phase ―Targeting treatments for infectious diseases that burden the developing world― https://www.tanabe-pharma.com/en/news/news20170601103038.html Thu, 01 Jun 2017 01:30:00 GMT db937c90-1968-4b0f-8201-ff7259a3ea0c 2017-06-01T01:30:00Z Approval for partial change in administration / dosage for Crohn’s disease for REMICADE® for I.V. Infusion 100, an anti-human TNFα monoclonal antibody https://www.tanabe-pharma.com/en/news/news20170518103011.html Thu, 18 May 2017 01:30:00 GMT 20d0c946-c49b-4056-8656-1bd59d1ce10a 2017-05-18T01:30:00Z Mitsubishi Tanabe Pharma announces The Lancet Neurology publication of the positive clinical results of Edaravone for ALS https://www.tanabe-pharma.com/en/news/news20170516103088.html Tue, 16 May 2017 01:30:00 GMT 8730a716-3ea2-4e9a-a20c-2a299c940694 2017-05-16T01:30:00Z Differences Between Non-Consolidated Actual Results for FY2015 and FY2016 https://www.tanabe-pharma.com/en/news/news20170510103061.html Wed, 10 May 2017 01:30:00 GMT 4baa205a-2a33-4ab7-b354-d6f65d885e74 2017-05-10T01:30:00Z Notice of Dividend of Retained Earnings https://www.tanabe-pharma.com/en/news/news20170510102961.html Wed, 10 May 2017 01:29:00 GMT 7b922186-6351-4db4-8385-094b0a2cc1e8 2017-05-10T01:29:00Z Notice Regarding Revision of Business Structure for Recombinant Human Serum Albumin Preparation https://www.tanabe-pharma.com/en/news/news20170510102858.html Wed, 10 May 2017 01:28:00 GMT 25e12f32-4f7c-4bfb-be22-70316bf77589 2017-05-10T01:28:00Z Establishment of Vaccine Manufacturing Joint Venture: BIKEN CO.,Ltd. https://www.tanabe-pharma.com/en/news/news20170509103078.html Tue, 09 May 2017 01:30:00 GMT 71bd532f-d43f-49e3-92e9-bb80883b889a 2017-05-09T01:30:00Z New Japan-originated ALS treatment option available to patients in the U.S. ―U.S. FDA approves RADICAVA™ (edaravone) for the treatment of ALS https://www.tanabe-pharma.com/en/news/news20170508103049.html Mon, 08 May 2017 01:30:00 GMT 09fc3bc3-e166-44c3-9d23-7045e312e035 2017-05-08T01:30:00Z Introduction of Performance-Linked Stock Compensation Plan for Board Directors https://www.tanabe-pharma.com/en/news/news20170426103047.html Wed, 26 Apr 2017 01:30:00 GMT 0b91797c-37c6-496b-a01d-c29f107d8b9c 2017-04-26T01:30:00Z Mitsubishi Tanabe Pharma Group receives import and marketing permission in Taiwan for CANAGLU® Tablets 100mg, a treatment agent for type 2 diabetes mellitus https://www.tanabe-pharma.com/en/news/news20170424103072.html Mon, 24 Apr 2017 01:30:00 GMT 7b2b04b1-5711-4d3c-b030-bcc716dcf6ed 2017-04-24T01:30:00Z Notice regarding overseas subsidiary MT Pharma (Thailand) Strengthening business development in the ASEAN region https://www.tanabe-pharma.com/en/news/news20170417103025.html Mon, 17 Apr 2017 01:30:00 GMT e462ba8e-6c8e-4f55-866a-28ca99ce8f57 2017-04-17T01:30:00Z Notice regarding approval of indication of ulcerative colitis and additional formulation for SIMPONI® subcutaneous injection 50mg syringe (generic name: golimumab), a human monoclonal antibody specific for human TNF α https://www.tanabe-pharma.com/en/news/news20170330103021.html Thu, 30 Mar 2017 01:30:00 GMT 039b9e80-4bba-4c88-b005-a67f3121ca14 2017-03-30T01:30:00Z Mitsubishi Tanabe Pharma and Daiichi Sankyo to Expand Strategic Alliance in the Diabetes Field The companies enter into a marketing alliance agreement for MT-2412, a combination drug for the treatment of type 2 diabetes mellitus, following co-operation for TENELIA® Tablets, a selective DPP-4 inhibitor, and CANAGLU® Tablets, an SGLT2 inhibitor https://www.tanabe-pharma.com/en/news/news20170329103073.html Wed, 29 Mar 2017 01:30:00 GMT f7a3a2e3-68ec-49a6-874d-e1a98e4c8ea4 2017-03-29T01:30:00Z Split off and transfer of Generic Drugs and Part of Long-Listed Products Business and Change of Subsidiary https://www.tanabe-pharma.com/en/news/news20170328103029.html Tue, 28 Mar 2017 01:30:00 GMT 07229098-206d-495e-82c7-8f0da3f6dcfc 2017-03-28T01:30:00Z Mitsubishi Tanabe Pharma Corporation Strategically Strengthens Its Foundation in the Field of Inflammatory Bowel Disease Mitsubishi Tanabe Pharma signs co-promotion agreement with Janssen Pharmaceutical K.K. for STELARA® for an indication of Crohn’s disease https://www.tanabe-pharma.com/en/news/news20170203103029.html Fri, 03 Feb 2017 01:30:00 GMT d29d2881-3db1-4fb0-a766-79e641b7f96a 2017-02-03T01:30:00Z Biogen and Mitsubishi Tanabe Pharma Terminate the License Agreement on MT-1303 https://www.tanabe-pharma.com/en/news/news20170127103063.html Fri, 27 Jan 2017 01:30:00 GMT a8fb579f-9036-47a4-bbf3-1f01f1a6ce63 2017-01-27T01:30:00Z 12-month Edaravone Clinical Study Data in ALS Presented at the 27th International Symposium on ALS/MND https://www.tanabe-pharma.com/en/news/news20161209103086.html Fri, 09 Dec 2016 01:30:00 GMT 863f9d78-6261-45bd-aecc-ea91ebf77b35 2016-12-09T01:30:00Z Basic Agreement on the Establishment of a Joint Venture https://www.tanabe-pharma.com/en/news/news20161107103027.html Mon, 07 Nov 2016 01:30:00 GMT 76578bee-889c-4921-9bb9-814ba54a2e02 2016-11-07T01:30:00Z Mitsubishi Tanabe Pharma Takes on the Challenge of Cell Therapy with the Conclusion of an Invossa Licensing Agreement with Kolon Life Science Aiming for therapy that addresses unmet medical needs in the treatment of knee osteoarthritis https://www.tanabe-pharma.com/en/news/news20161101103078.html Tue, 01 Nov 2016 01:30:00 GMT 79541c21-04e6-4872-95fe-ce7e14818a76 2016-11-01T01:30:00Z Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2017 https://www.tanabe-pharma.com/en/news/news20161025103097.html Tue, 25 Oct 2016 01:30:00 GMT 7544306c-78b3-4f14-a6b9-425f75fa4538 2016-10-25T01:30:00Z Joint research identifies hit compounds for the development of a new treatment for malaria Mitsubishi Tanabe Pharma uses its compound library in joint research activities with Medicines for Malaria Venture ―Targeting treatments for infectious diseases that burden the developing world― https://www.tanabe-pharma.com/en/news/news20161005103085.html Wed, 05 Oct 2016 01:30:00 GMT b2f7f1c3-a80d-4422-8121-f61ae75342a8 2016-10-05T01:30:00Z Execution of Basic Agreement for Sales Anti-Allergy Agent, Rupatadine Tablets https://www.tanabe-pharma.com/en/news/news20161004103088.html Tue, 04 Oct 2016 01:30:00 GMT 23e2ee8b-80b5-40c7-bbe2-950c8ecdfcd6 2016-10-04T01:30:00Z Regarding Edaravone Access in U.S. https://www.tanabe-pharma.com/en/news/news20160929103077.html Thu, 29 Sep 2016 01:30:00 GMT c410b18a-1542-4a9a-bf42-4f1ff9c8f329 2016-09-29T01:30:00Z Application for partial change in administration/dosage for Crohn's disease for REMICADE® for I.V. Infusion 100, an anti-human TNFα monoclonal antibody https://www.tanabe-pharma.com/en/news/news20160906103078.html Tue, 06 Sep 2016 01:30:00 GMT fcfd3209-9bbc-4240-b768-60715f6db82d 2016-09-06T01:30:00Z FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALS https://www.tanabe-pharma.com/en/news/news20160830103092.html Tue, 30 Aug 2016 01:30:00 GMT 160f5b56-7c7e-4182-9cb6-df83787f7872 2016-08-30T01:30:00Z Valixa® Tablet 450mg Approval for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patients https://www.tanabe-pharma.com/en/news/news20160826103018.html Fri, 26 Aug 2016 01:30:00 GMT beec05ea-1785-4f63-aab8-02e13d376b97 2016-08-26T01:30:00Z Application filed in Japan fortype 2 diabetes mellitus treatment agent combination drug - Combination of selective DPP-4 inhibitor TENELIA® Tablets and SGLT2 inhibitor CANAGLU® Tablets - https://www.tanabe-pharma.com/en/news/news20160823103014.html Tue, 23 Aug 2016 01:30:00 GMT 49fb532c-b31b-48c0-8e4e-fc17a21d1a4f 2016-08-23T01:30:00Z Regarding Nomination Committee and Compensation Committee https://www.tanabe-pharma.com/en/news/news20160622103053.html Wed, 22 Jun 2016 01:30:00 GMT 4954e256-e895-4caa-96fc-0357158a345d 2016-06-22T01:30:00Z Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United States https://www.tanabe-pharma.com/en/news/news20160620103079.html Mon, 20 Jun 2016 01:30:00 GMT 12c19dc6-ffd2-41f7-bff8-a6da97d9d497 2016-06-20T01:30:00Z Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund https://www.tanabe-pharma.com/en/news/news20160606103019.html Mon, 06 Jun 2016 01:30:00 GMT 2c6a5e6e-f341-4868-a578-973b369ee31f 2016-06-06T01:30:00Z Approval of REMICADE® for I.V. Infusion 100, an Anti-Human TNFα Monoclonal Antibody, for a Partial Change in Dosage and Usage in Psoriasis https://www.tanabe-pharma.com/en/news/news20160513103019.html Fri, 13 May 2016 01:30:00 GMT f3f437ff-fba3-40d6-a6f0-af0d44d80e25 2016-05-13T01:30:00Z Corrections with respect to “Summary of Financial Results for year ended March 31, 2016”　(Japan GAAP) (Consolidated) https://www.tanabe-pharma.com/en/news/news20160513102993.html Fri, 13 May 2016 01:29:00 GMT 166ca56f-5723-4b7b-8adb-82a13f8236b6 2016-05-13T01:29:00Z Notice of Dividend of Retained Earnings https://www.tanabe-pharma.com/en/news/news20160511103027.html Wed, 11 May 2016 01:30:00 GMT 8339eb2f-e286-42a5-8dd2-f0f6351257f6 2016-05-11T01:30:00Z Change of Representative Director, Director and Corporate Auditor https://www.tanabe-pharma.com/en/news/news20160427103037.html Wed, 27 Apr 2016 01:30:00 GMT 861bd7aa-4edb-45b2-ba29-58234a87b55c 2016-04-27T01:30:00Z Mitsubishi Tanabe Pharma Corporation Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual Meeting https://www.tanabe-pharma.com/en/news/news20160420103078.html Wed, 20 Apr 2016 01:30:00 GMT 9faa93ca-5974-4567-8caa-d50ab3b3398f 2016-04-20T01:30:00Z MT Pharma Singapore Pte. Ltd. Starts Business Operations Mitsubishi Tanabe Pharma's Subsidiary in Singapore https://www.tanabe-pharma.com/en/news/news20160404103053.html Mon, 04 Apr 2016 01:30:00 GMT 5de0efca-b3fd-4da1-99a1-55ec3fdff5f5 2016-04-04T01:30:00Z Astellas and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound Libraries https://www.tanabe-pharma.com/en/news/news20160329103014.html Tue, 29 Mar 2016 01:30:00 GMT f86f7981-984b-42ad-ab8a-acf71c48bf93 2016-03-29T01:30:00Z Valixa® Tablet 450 mg Application for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patients Public Knowledge-based Application https://www.tanabe-pharma.com/en/news/news20160322103025.html Tue, 22 Mar 2016 01:30:00 GMT c4ce69ef-2d42-408e-9f63-827929cc45e7 2016-03-22T01:30:00Z Notice regarding change of current commercialization scheme to new strategic co-promotion partnership in Japan for RA treatment agent Simponi® subcutaneous injection 50 mg syringe (generic name: golimumab) https://www.tanabe-pharma.com/en/news/news20160310103013.html Thu, 10 Mar 2016 01:30:00 GMT 5d1d977d-b70a-4c41-ace8-7d5401d4f98a 2016-03-10T01:30:00Z Mitsubishi Tanabe Pharma Enhances Operations in the United States https://www.tanabe-pharma.com/en/news/news20160223103042.html Tue, 23 Feb 2016 01:30:00 GMT efa1bd23-e170-4e12-bbf5-a777f94c4e0c 2016-02-23T01:30:00Z Notice Regarding Results of Early Retirement Program https://www.tanabe-pharma.com/en/news/news20160203103020.html Wed, 03 Feb 2016 01:30:00 GMT 7488c2b7-6164-48b4-88e9-6284ead90550 2016-02-03T01:30:00Z Remicade® for I.V. Infusion 100 Approval of Additional Indication for Kawasaki Disease World First Biologic Treatment https://www.tanabe-pharma.com/en/news/news20151221103061.html Mon, 21 Dec 2015 01:30:00 GMT d88fb00a-bad4-4ae1-9664-d96cc2d27184 2015-12-21T01:30:00Z RADICUT® inj. 30mg and RADICUT® Infusion inj. 30mg An import and Marketing Permission for ALS in South Korea https://www.tanabe-pharma.com/en/news/news20151221102967.html Mon, 21 Dec 2015 01:29:00 GMT 3c67d6f5-e5ea-4f9a-ac3b-22e3e9c6557d 2015-12-21T01:29:00Z Akebia and Mitsubishi Tanabe Pharma Announce Collaboration to Develop and Commercialize Vadadustat in Asia https://www.tanabe-pharma.com/en/news/news20151215103086.html Tue, 15 Dec 2015 01:30:00 GMT 5c077f23-364e-4046-b41a-6387b02ff77d 2015-12-15T01:30:00Z Formulation of the Medium-Term Management Plan 16-20: Open Up the Future https://www.tanabe-pharma.com/en/news/news20151130103037.html Mon, 30 Nov 2015 01:30:00 GMT d884720c-c495-4373-ac55-b5c0801b5dd2 2015-11-30T01:30:00Z Announcement of an approval for an additional indication for the Anti-depressant, Lexapro® Tablets 10 mg in Japan https://www.tanabe-pharma.com/en/news/news20151120103051.html Fri, 20 Nov 2015 01:30:00 GMT 5c61ed03-39dd-474c-a509-ae1c17752bcb 2015-11-20T01:30:00Z Notice Regarding Implementation of Early Retirement Program https://www.tanabe-pharma.com/en/news/news20151030103076.html Fri, 30 Oct 2015 01:30:00 GMT 88ef0cb8-e6b0-4b1d-8ba4-007596b4bfb2 2015-10-30T01:30:00Z Medicago Engaged by the Canadian Government Produce Ebola Monoclonal Antibodies https://www.tanabe-pharma.com/en/news/news20151030102979.html Fri, 30 Oct 2015 01:29:00 GMT 68299b5f-88c4-47f5-b0f2-5843ccca9514 2015-10-30T01:29:00Z Mitsubishi Tanabe Pharma and Regeneron Conclude Collaboration Agreement for Fasinumab, NGF Antibody https://www.tanabe-pharma.com/en/news/news20151002103073.html Fri, 02 Oct 2015 01:30:00 GMT 56fa0682-52bd-403b-85dc-dcf8392042c2 2015-10-02T01:30:00Z Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2016 https://www.tanabe-pharma.com/en/news/news20150930103013.html Wed, 30 Sep 2015 01:30:00 GMT 5063a7a6-7fcb-4ad2-9e75-57c2cb27f060 2015-09-30T01:30:00Z MedImmune and Tanabe Research Laboratories / Mitsubishi Tanabe Pharma Enter into Strategic Collaboration and Licensing Agreement for the Development of Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugates to Treat Cancer https://www.tanabe-pharma.com/en/news/news20150923103016.html Wed, 23 Sep 2015 01:30:00 GMT b789ce0c-1bd5-4862-8533-a490e77ea911 2015-09-23T01:30:00Z Notice Regarding Worldwide Patent and Know-how Transfer, Excluding Japan and Certain Other Territories in Asia, for TA-8995 (CETP inhibitor), a Treatment Agent for Dyslipidemia https://www.tanabe-pharma.com/en/news/news20150917103089.html Thu, 17 Sep 2015 01:30:00 GMT dd8e8053-baa4-45a8-a734-edd73d1ae56e 2015-09-17T01:30:00Z MT-4666 in Alzheimer’s Disease Discontinuation of Global Phase 3 Clinical Trial Program in Japan https://www.tanabe-pharma.com/en/news/news20150915103062.html Tue, 15 Sep 2015 01:30:00 GMT 933d4c61-d5a9-4757-a90a-4b907b1b9720 2015-09-15T01:30:00Z Biogen and Mitsubishi Tanabe Pharma Conclude a License Agreement on MT-1303, a Therapeutic Agent for Autoimmune Diseases https://www.tanabe-pharma.com/en/news/news20150909103088.html Wed, 09 Sep 2015 01:30:00 GMT 46a95002-1d2b-4137-9ef2-c80bc283f556 2015-09-09T01:30:00Z Approval of REMICADE® for I.V. Infusion 100, an Anti-Human TNFα Monoclonal Antibody, for Additional Indications for Entero-Behcet's Disease, Neuro-Behcet's Disease, and Vasculo-Behcet's Disease https://www.tanabe-pharma.com/en/news/news20150824103047.html Mon, 24 Aug 2015 01:30:00 GMT 04376362-545e-471d-bbd1-faa82b7000a3 2015-08-24T01:30:00Z Organizational Restructuring https://www.tanabe-pharma.com/en/news/news20150727103058.html Mon, 27 Jul 2015 01:30:00 GMT c641e41f-17fd-454d-8dcb-0fb81d7a226f 2015-07-27T01:30:00Z Application Filed for a Partial Change in Dosage and Usage of REMICADE® for I.V. Infusion 100, an Anti-Human TNFα Monoclonal Antibody, in Psoriasis https://www.tanabe-pharma.com/en/news/news20150710103084.html Fri, 10 Jul 2015 01:30:00 GMT 47771e52-6e16-4be9-8075-f81e913fe308 2015-07-10T01:30:00Z RADICUT® inj. 30mg and RADICUT® BAG for I.V. Infusion 30mg Mitsubishi Tanabe Pharma Corporation receives approval for additional indication for Amyotrophic Lateral Sclerosis (ALS) in Japan https://www.tanabe-pharma.com/en/news/news20150626103085.html Fri, 26 Jun 2015 01:30:00 GMT cbd126df-77d6-4a01-9f83-f366b82476e8 2015-06-26T01:30:00Z Approval for Additional Pediatric Indications in Japan Received for TALION® Tablets and TALION® OD Tablets, Anti-Allergic Agents https://www.tanabe-pharma.com/en/news/news20150526103079.html Tue, 26 May 2015 01:30:00 GMT 8f05e767-d01f-4e68-b8ac-58276ceaf706 2015-05-26T01:30:00Z Mitsubishi Tanabe Pharma provides Compound Library to Screening Program of Global Health Innovative Technology Fund https://www.tanabe-pharma.com/en/news/news20150522103083.html Fri, 22 May 2015 01:30:00 GMT e5e5f8b3-6a03-47ce-b701-61caf7f5dac8 2015-05-22T01:30:00Z Application filed for REMICADE? for I.V. Infusion 100, an anti-human TNFα monoclonal antibody, for an additional indication for Kawasaki disease https://www.tanabe-pharma.com/en/news/news20150515103082.html Fri, 15 May 2015 01:30:00 GMT be0470ef-0f9c-45a9-b155-fff70e88d93e 2015-05-15T01:30:00Z Notice of Dividend of Retained Earnings https://www.tanabe-pharma.com/en/news/news20150508103082.html Fri, 08 May 2015 01:30:00 GMT 2c427dc5-d8d9-4e39-ba12-9631f39ee94c 2015-05-08T01:30:00Z Execution of License Agreement on VMAT2 Inhibitor NBI-98854 https://www.tanabe-pharma.com/en/news/news20150401103065.html Wed, 01 Apr 2015 01:30:00 GMT f383c383-47a9-4570-8797-7dc19b016f5d 2015-04-01T01:30:00Z Medicago Develops Alternative Production Process for Ebola Antibodies Contract concluded with U.S. government https://www.tanabe-pharma.com/en/news/news20150225103022.html Wed, 25 Feb 2015 01:30:00 GMT ceb30b69-0a84-429e-9468-f47e2e6ecfe7 2015-02-25T01:30:00Z Reorganization of research bases in Japan https://www.tanabe-pharma.com/en/news/news20150225102963.html Wed, 25 Feb 2015 01:29:00 GMT 7c71124d-7d2c-48f2-814d-08ee730d9822 2015-02-25T01:29:00Z Completion of Construction of the New Head Office Building https://www.tanabe-pharma.com/en/news/news20150206103020.html Fri, 06 Feb 2015 01:30:00 GMT 97df5447-3d8c-4db9-8661-52807538cb49 2015-02-06T01:30:00Z -Increasing Production Capacity to Meet Growing Asian Pharmaceutical Markets -Completion of New Manufacturing FacilityTianjin Tanabe Seiyaku Co., Ltd. and P.T. Tanabe Indonesia https://www.tanabe-pharma.com/en/news/news20150129103094.html Thu, 29 Jan 2015 01:30:00 GMT d7ba670c-cc6b-4a43-9a47-e0523b646657 2015-01-29T01:30:00Z Reorganization of the U.S. Affiliates to Accelerate the U.S. Operations Expansion https://www.tanabe-pharma.com/en/news/news20141218103059.html Thu, 18 Dec 2014 01:30:00 GMT 744c2b0d-95f4-4a9a-a3c3-96589c5434a2 2014-12-18T01:30:00Z Notice regarding conclusion of the final agreement for the transfer of the Kashima Plant of Mitsubishi Tanabe Pharma Factory Ltd. https://www.tanabe-pharma.com/en/news/news20141128103092.html Fri, 28 Nov 2014 01:30:00 GMT 1de0bc23-673f-4543-bce5-b4decf9ec0ed 2014-11-28T01:30:00Z Application filed for additional indication for ALS for RADICUT® inj. 30mg and RADICUT BAG for I.V. Infusion 30mg https://www.tanabe-pharma.com/en/news/news20141113103091.html Thu, 13 Nov 2014 01:30:00 GMT 3d344d21-7997-471a-9e5f-8243981d3dad 2014-11-13T01:30:00Z Supporting “good blood glucose control” in Japanese patients with diabetes joint promotion with Johnson & Johnson K.K. Medical Company https://www.tanabe-pharma.com/en/news/news20141106103019.html Thu, 06 Nov 2014 01:30:00 GMT 0f6fc20d-6933-40ab-a812-c0ffe262cd17 2014-11-06T01:30:00Z Applications filed for REMICADE® for I.V. Infusion 100, an anti-human TNFα monoclonal antibody, for additional indications for entero-Behcet’s disease, neuro-Behcet’s disease, and vasculo-Behcet’s disease https://www.tanabe-pharma.com/en/news/news20141030103071.html Thu, 30 Oct 2014 01:30:00 GMT 0a17d6a7-1c06-4cd6-bf3f-31e200b71f76 2014-10-30T01:30:00Z Revisions to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2015 https://www.tanabe-pharma.com/en/news/news20141021103039.html Tue, 21 Oct 2014 01:30:00 GMT 90501242-aaa6-4250-a93f-cc8925f382c8 2014-10-21T01:30:00Z TELAVIC® 250mg Tablets, Antiviral Approval of Additional indication for Chronic Hepatitis C Genotype 2 https://www.tanabe-pharma.com/en/news/news20140919103031.html Fri, 19 Sep 2014 01:30:00 GMT a5bded0f-4ca8-4675-859e-2ad36d19904b 2014-09-19T01:30:00Z Launch of CANAGLU® Tablets 100mg A SGLT2 inhibitor for Type2 Diabetes Mellitus https://www.tanabe-pharma.com/en/news/news20140902103072.html Tue, 02 Sep 2014 01:30:00 GMT f87907bd-e9bd-4032-a1f8-0bee4c820d48 2014-09-02T01:30:00Z MITSUBISHI TANABE PHARMA CORPORATION AND ASTRAZENECA ANNOUNCE RESEARCH COLLABORATION IN DIABETIC NEPHROPATHY https://www.tanabe-pharma.com/en/news/news20140820103083.html Wed, 20 Aug 2014 01:30:00 GMT afef0c89-12bf-4cae-a5f4-f66e7a6c3144 2014-08-20T01:30:00Z Marketing and Manufacturing Approval in Japan Received for CANAGLU® Tablets 100mg https://www.tanabe-pharma.com/en/news/news20140704103088.html Fri, 04 Jul 2014 01:30:00 GMT fd4ac882-9f2d-47b1-9669-e2aecf931fb6 2014-07-04T01:30:00Z Notice regarding conclusion of a basic agreement for the transfer of the Kashima Plant of Mitsubishi Tanabe Pharma Factory Ltd. https://www.tanabe-pharma.com/en/news/news20140630103016.html Mon, 30 Jun 2014 01:30:00 GMT a2d9c760-1598-4399-8d86-dd1f70d5e623 2014-06-30T01:30:00Z Notice Regarding Voluntary Adoption of International Financial Reporting Standards (IFRS) https://www.tanabe-pharma.com/en/news/news20140630102919.html Mon, 30 Jun 2014 01:29:00 GMT 7f4dc84d-8389-49ae-892a-c15c7d6087fb 2014-06-30T01:29:00Z Positive Phase 3 Results of Canagliflozin in Japanese Patients with Type 2 Diabetes at American Diabetes Association https://www.tanabe-pharma.com/en/news/news20140616103086.html Mon, 16 Jun 2014 01:30:00 GMT 522c77aa-588d-41f0-a9b2-e3fc73a73a27 2014-06-16T01:30:00Z Name Change of Group Company in China https://www.tanabe-pharma.com/en/news/news20140530103079.html Fri, 30 May 2014 01:30:00 GMT e8abfe0a-6ffc-4136-bca2-dc5f9ba5acf2 2014-05-30T01:30:00Z Announcement of Merger (Simplified Merger and Short form Merger) of Consolidated Subsidiary https://www.tanabe-pharma.com/en/news/news20140529103098.html Thu, 29 May 2014 01:30:00 GMT 6e37a1c3-5cdf-4b78-acd3-22ac6c3cd6ee 2014-05-29T01:30:00Z Name Change of Consolidated Subsidiaries in Europe https://www.tanabe-pharma.com/en/news/news20140528103041.html Wed, 28 May 2014 01:30:00 GMT 33f9422e-17a0-4d03-9c5d-dd16dbf26aa2 2014-05-28T01:30:00Z Change of Representative Directors and Personnel https://www.tanabe-pharma.com/en/news/MTPC140423.html Wed, 23 Apr 2014 01:30:00 GMT a2f92b5d-c9d1-428b-9c98-9ceb24258f8a 2014-04-23T01:30:00Z Change of Representative Directors https://www.tanabe-pharma.com/en/news/news20140206103063.html Thu, 06 Feb 2014 01:30:00 GMT 608fc8e6-9b56-48d9-a183-a14fc90a8b71 2014-02-06T01:30:00Z MT-4666 in Alzheimer’s DiseaseStart of Global Phase 3 Clinical Trial Program, COGNITIV AD https://www.tanabe-pharma.com/en/news/news20140203103091.html Mon, 03 Feb 2014 01:30:00 GMT f47cfca0-0947-4532-ab56-b5a6fc225788 2014-02-03T01:30:00Z TELAVIC® 250mg Tablets, Antiviral Application for additional Indication for Chronic Hepatitis C Genotype 2 https://www.tanabe-pharma.com/en/news/news20140116103021.html Thu, 16 Jan 2014 01:30:00 GMT 82c05a0c-ac28-4c02-94de-dfdc75d48600 2014-01-16T01:30:00Z TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Approval of Partial Change in Indication to Lift Restrictions in Combination Therapy https://www.tanabe-pharma.com/en/news/news20131220103053.html Fri, 20 Dec 2013 01:30:00 GMT 18a43b6d-aba8-4315-bc1d-2dd3b9412f90 2013-12-20T01:30:00Z Regarding Administrative Action Related to Violation of Pharmaceutical Affairs Law of Japan https://www.tanabe-pharma.com/en/news/news20130930103034.html Mon, 30 Sep 2013 01:30:00 GMT 9ae1050f-f1ce-4dd8-8fd5-c6cf697dac57 2013-09-30T01:30:00Z Revision to 2Q Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2014 https://www.tanabe-pharma.com/en/news/news20130925103087.html Wed, 25 Sep 2013 01:30:00 GMT 323e124f-6847-4b1a-9bdc-60b001947811 2013-09-25T01:30:00Z Mitsubishi Tanabe Pharma to Open Singapore Office https://www.tanabe-pharma.com/en/news/news20130919103053.html Thu, 19 Sep 2013 01:30:00 GMT 6bd48827-2989-4ef7-b73e-520978e0e4c5 2013-09-19T01:30:00Z Notice Regarding Completion of Acquisition of Shares of Medicago, Inc., a Pharmaceutical Company Based in Canada, Which Has Become a Subsidiary of Mitsubishi Tanabe Pharma https://www.tanabe-pharma.com/en/news/news20130919102983.html Thu, 19 Sep 2013 01:29:00 GMT fac1c850-249f-4662-aba4-4a4e64717fc7 2013-09-19T01:29:00Z Tanabe Indonesia to Construct New Production Facility in Indonesia https://www.tanabe-pharma.com/en/news/news20130909103064.html Mon, 09 Sep 2013 01:30:00 GMT c81e7b38-7d7c-42f6-b31a-3b69e3f2bdbe 2013-09-09T01:30:00Z Notice Regarding Arbitration Award in Dispute with Janssen Biotech, Inc. https://www.tanabe-pharma.com/en/news/news20130808103054.html Thu, 08 Aug 2013 01:30:00 GMT 0f224a68-ff7e-44f3-9186-d57099a14283 2013-08-08T01:30:00Z Tianjin Tanabe Seiyaku to Construct New Production Facility in China https://www.tanabe-pharma.com/en/news/news20130806103032.html Tue, 06 Aug 2013 01:30:00 GMT 6537f3dd-a7d0-4307-bc7a-4cd3fa0ea747 2013-08-06T01:30:00Z Notice regarding the reorganization of Mitsubishi Tanabe Pharma Factory Ltd.'s domestic production sites and the conclusion of a basic agreement regarding the transfer of its Ashikaga Plant https://www.tanabe-pharma.com/en/news/news20130801103016.html Thu, 01 Aug 2013 01:30:00 GMT a0afd4e0-546b-4861-a19d-42282658dd69 2013-08-01T01:30:00Z Notice regarding the acquisition of Medicago Inc. https://www.tanabe-pharma.com/en/news/news20130712103065.html Fri, 12 Jul 2013 01:30:00 GMT af467afe-15fe-4c63-92cc-7efbc1a90f43 2013-07-12T01:30:00Z VIVUS gains MAA approval for TA-1790 in the EU https://www.tanabe-pharma.com/en/news/news20130627103090.html Thu, 27 Jun 2013 01:30:00 GMT a4fa6cd3-cb15-48e1-b15d-e4e9c179d625 2013-06-27T01:30:00Z Approval for Additional Indication for Atrial Fibrillation (Tachycardiac ) MAINTATE® Tablets: Selective β1 Blocker https://www.tanabe-pharma.com/en/news/news20130614103040.html Fri, 14 Jun 2013 01:30:00 GMT 5070523e-42d4-4da7-9451-af87645d049f 2013-06-14T01:30:00Z New Drug Application Filed in Japan for TA-7284 (Canagliflozin) To Treat Patients with Type 2 Diabetes https://www.tanabe-pharma.com/en/news/news20130527103048.html Mon, 27 May 2013 01:30:00 GMT d24926aa-4629-46e8-aa0e-56d55b90291f 2013-05-27T01:30:00Z Change of Directors https://www.tanabe-pharma.com/en/news/news20130430103099.html Tue, 30 Apr 2013 01:30:00 GMT 583dcd8b-0765-41bb-9d86-84828f2cd09a 2013-04-30T01:30:00Z Launch of BindRen® for Treatment of Hyperphosphatemia in Germany and Austria https://www.tanabe-pharma.com/en/news/news20130403103079.html Wed, 03 Apr 2013 01:30:00 GMT f8540a58-d7d2-48e0-b613-179409d32ffb 2013-04-03T01:30:00Z Transfer of Tanabe Europe’s shares https://www.tanabe-pharma.com/en/news/news20130401103048.html Mon, 01 Apr 2013 01:30:00 GMT 96bd37ad-39ec-448c-a1b9-1ac3fbb6d052 2013-04-01T01:30:00Z U.S. FDA Approves Canagliflozin (TA-7284) for the Treatment of Adult Patients with Type 2 Diabetes https://www.tanabe-pharma.com/en/news/news20130401102991.html Mon, 01 Apr 2013 01:29:00 GMT dedc2d61-ce99-4f77-aa00-c33d18106cb8 2013-04-01T01:29:00Z Approval for time-window extension of the thrombolytic agents GRTPA® and ACTIVACIN® up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular disease https://www.tanabe-pharma.com/en/news/news20130228103084.html Thu, 28 Feb 2013 01:30:00 GMT a5c111e3-af3b-485a-8376-365b491861dd 2013-02-28T01:30:00Z TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Application for Partial Change in Indications for Combination Therapy https://www.tanabe-pharma.com/en/news/news20130226103065.html Tue, 26 Feb 2013 01:30:00 GMT b3cedf6e-7df7-4701-bc16-63bf094fc9a2 2013-02-26T01:30:00Z Helicobacter pylori Gastritis Approved as Additional Indication in Japan for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitor https://www.tanabe-pharma.com/en/news/news20130221103053.html Thu, 21 Feb 2013 01:30:00 GMT 76988458-89d9-4224-bf77-5fe7e2040de9 2013-02-21T01:30:00Z BindRen® Granted Marketing Authorization in Europe for Treatment of Hyperphosphatemia https://www.tanabe-pharma.com/en/news/news20130129103056.html Tue, 29 Jan 2013 01:30:00 GMT 8b118519-82aa-4023-8a40-9bf73aa9b8f9 2013-01-29T01:30:00Z Launch of TETRABIK Adsorbed Diphtheria-purified Pertussis-tetanus inactivated polio (Sabin strain) Combined Vaccine https://www.tanabe-pharma.com/en/news/news20121026103054.html Fri, 26 Oct 2012 01:30:00 GMT 9078941e-9364-4c4e-a7a7-8acf82475b4a 2012-10-26T01:30:00Z Notice Regarding Dissolution of Capital Alliance with Choseido Pharmaceutical Co., Ltd. https://www.tanabe-pharma.com/en/news/news20121019103027.html Fri, 19 Oct 2012 01:30:00 GMT c41e47df-47e9-4604-b2aa-0174b5726240 2012-10-19T01:30:00Z Outcome of Global Phase III (EPPIC) Studies https://www.tanabe-pharma.com/en/news/news20121010103058.html Wed, 10 Oct 2012 01:30:00 GMT 309a0367-b5fe-427c-a62b-7e571d39d851 2012-10-10T01:30:00Z Outsourcing of Logistics Operations https://www.tanabe-pharma.com/en/news/news20121001103089.html Mon, 01 Oct 2012 01:30:00 GMT a9534648-0840-4250-a089-036b4c3505b0 2012-10-01T01:30:00Z Application for time-window extension of the thrombolytic agents GRTPA® and ACTIVACIN® up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular disease https://www.tanabe-pharma.com/en/news/news20120928103030.html Fri, 28 Sep 2012 01:30:00 GMT a3c01db9-0def-47ba-81ae-8748f62429e5 2012-09-28T01:30:00Z Launch of "Simponi®”, a human TNFα monoclonal antibody in Indonesia https://www.tanabe-pharma.com/en/news/news20120920103079.html Thu, 20 Sep 2012 01:30:00 GMT f8d12230-3fba-4e38-be4f-5c14123bbc5c 2012-09-20T01:30:00Z MAINTATE® Tablets: Selective β1 AntagonistNotice regarding application for additional indication for chronic atrial fibrillation https://www.tanabe-pharma.com/en/news/news20120913103087.html Thu, 13 Sep 2012 01:30:00 GMT 247bf47e-fb1e-4514-b9d6-c2ccf88bb4a5 2012-09-13T01:30:00Z Companies Submit Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or Metronidazole https://www.tanabe-pharma.com/en/news/news20120831103096.html Fri, 31 Aug 2012 01:30:00 GMT 72324fe7-7514-474e-9720-77ce46252b5c 2012-08-31T01:30:00Z Notice regarding dissolution of Bipha Corporation-related joint venture with Nipro Corporation https://www.tanabe-pharma.com/en/news/news20120831102950.html Fri, 31 Aug 2012 01:29:00 GMT 5992e291-9b13-4b1f-88e4-458a58af7321 2012-08-31T01:29:00Z Launch of TENELIA® 20mg TabletsA DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan https://www.tanabe-pharma.com/en/news/news20120828103093.html Tue, 28 Aug 2012 01:30:00 GMT 45c58961-4002-45a1-bf26-d6242bf75f9d 2012-08-28T01:30:00Z Launch of Tranquilizer, DEPAS® TABLETS 0.25 mg https://www.tanabe-pharma.com/en/news/news20120723103064.html Mon, 23 Jul 2012 01:30:00 GMT 402570d1-d890-4c13-b7dd-97e7752f4e78 2012-07-23T01:30:00Z Launch of Argatroban, a Selective Antithrombin Agent, in UK https://www.tanabe-pharma.com/en/news/news20120706103049.html Fri, 06 Jul 2012 01:30:00 GMT fefac4e8-a058-41b3-9435-911ea5a65762 2012-07-06T01:30:00Z Marketing and Manufacturing Approval Received for TENELIA® 20mg Tablets A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan https://www.tanabe-pharma.com/en/news/news20120629103080.html Fri, 29 Jun 2012 01:30:00 GMT 401772f1-b5c2-4e2d-b7f5-b2cef3cb40f3 2012-06-29T01:30:00Z Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Taiwan https://www.tanabe-pharma.com/en/news/news20120606103046.html Wed, 06 Jun 2012 01:30:00 GMT fcc94633-4158-43cf-87a9-5ef9b756724d 2012-06-06T01:30:00Z Termination of License Agreement with Cytochroma for MT-2832 (Generic Name: Lunacalcipol) as a Treatment for Secondary Hyperparathyroidism https://www.tanabe-pharma.com/en/news/news20120601103075.html Fri, 01 Jun 2012 01:30:00 GMT 850569b4-9a6b-46c5-a8fc-319cd1f3366f 2012-06-01T01:30:00Z Notice Regarding Transfer of Fine Chemical Operations https://www.tanabe-pharma.com/en/news/news20120515103092.html Tue, 15 May 2012 01:30:00 GMT 8f4d9182-b626-4944-9275-349968e99358 2012-05-15T01:30:00Z Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Indonesia https://www.tanabe-pharma.com/en/news/news20120509103019.html Wed, 09 May 2012 01:30:00 GMT 7405b1ec-d745-4a65-9412-4e2c763e427b 2012-05-09T01:30:00Z Notice of Dividend of Retained Earnings https://www.tanabe-pharma.com/en/news/news20120508103031.html Tue, 08 May 2012 01:30:00 GMT bc9934c7-1d9d-4424-89f2-77e5f63c3c45 2012-05-08T01:30:00Z New Organization in Plasma Fractionation Operations Establishment of “Japan Blood Products Organization” https://www.tanabe-pharma.com/en/news/news20120508102954.html Tue, 08 May 2012 01:29:00 GMT e42e626a-8218-44c5-9056-98163d596117 2012-05-08T01:29:00Z Remicade® for I.V. Infusion 100, Anti-Human TNF α Monoclonal Antibody A New Option to Shorten Infusion Time https://www.tanabe-pharma.com/en/news/news20120508102839.html Tue, 08 May 2012 01:28:00 GMT 246cc85d-ab7b-4011-b00e-c05fd5c747c2 2012-05-08T01:28:00Z Remicade® for I.V. Infusion 100, Anti-Human TNF α Monoclonal Antibody Lifting of Condition on Approval for Psoriasis https://www.tanabe-pharma.com/en/news/news20120508102790.html Tue, 08 May 2012 01:27:00 GMT 6be594f2-446d-40ce-a127-ffb2f3071544 2012-05-08T01:27:00Z VIVUS gains NDA approval for TA-1790 in the US https://www.tanabe-pharma.com/en/news/news20120507103087.html Mon, 07 May 2012 01:30:00 GMT 489da036-9c54-4d15-b3ce-0c171d30593b 2012-05-07T01:30:00Z Launch of "SIMPONI™”, a human TNFα monoclonal antibody in Taiwan https://www.tanabe-pharma.com/en/news/news20120329103084.html Thu, 29 Mar 2012 01:30:00 GMT 9fbd686c-eab7-4559-9f5e-5fbe66a61a89 2012-03-29T01:30:00Z “IMUSERA® Capsules 0.5mg” Multiple Sclerosis Treatment Agent Notice regarding revision of “warnings” and “important basic precautions” sections of prescribing information https://www.tanabe-pharma.com/en/news/news20120321103096.html Wed, 21 Mar 2012 01:30:00 GMT be935752-358a-4e26-a8e4-87a1f9b46b52 2012-03-21T01:30:00Z Conclusion of Research Collaboration Agreement for Next-Generation Vaccines https://www.tanabe-pharma.com/en/news/news20120307103073.html Wed, 07 Mar 2012 01:30:00 GMT c0c488b4-31df-41a0-a4dc-847892d5d187 2012-03-07T01:30:00Z Daiichi Sankyo and Mitsubishi Tanabe Pharma Establish Strategic Alliance to Contribute to the Treatment of Diabetes in Japan Companies conclude joint sales agreement for two treatments for type 2 diabetes mellitus - MP-513 and TA-7284 https://www.tanabe-pharma.com/en/news/news20120306103014.html Tue, 06 Mar 2012 01:30:00 GMT add4fb19-aff0-4bad-bceb-169907566661 2012-03-06T01:30:00Z Conclusion of Licensing Agreement for Hib Vaccine https://www.tanabe-pharma.com/en/news/news20120116103084.html Mon, 16 Jan 2012 01:30:00 GMT 28154b58-4a67-4e4d-b269-d12cc4cf211a 2012-01-16T01:30:00Z Dainippon Sumitomo Pharma and Yoshitomiyakuhin terminate co-promotion of antipsychotics, LONASEN® and LULLAN® https://www.tanabe-pharma.com/en/news/news20111201103065.html Thu, 01 Dec 2011 01:30:00 GMT 86acb0a3-5502-4c32-8e7d-e4f4e6380c05 2011-12-01T01:30:00Z Launch of "IMUSERA® Capsules 0.5mg" Japan's First Oral Dosing Multiple Sclerosis Treatment with Novel Mode of Action https://www.tanabe-pharma.com/en/news/news20111125103026.html Fri, 25 Nov 2011 01:30:00 GMT e13ab80a-2789-4917-b4c0-fe5ad39ffe57 2011-11-25T01:30:00Z Launch of Antiviral Agent "TELAVIC® Tablets 250 mg" Novel Mode of Action for Chronic Hepatitis C Treatment https://www.tanabe-pharma.com/en/news/news20111125102958.html Fri, 25 Nov 2011 01:29:00 GMT 5591f870-f3c4-4417-aaeb-60671f764663 2011-11-25T01:29:00Z Approval of Additional Indication for MODIODAL® Tablets 100 mg a Sleep Disorder Treatment https://www.tanabe-pharma.com/en/news/news20111125102836.html Fri, 25 Nov 2011 01:28:00 GMT 9e866e7c-a10c-430b-97ba-5faf1a158ed0 2011-11-25T01:28:00Z Notice of postponement of integrating the plasma fractionation operations of the Japanese Red Cross Society and Mitsubishi Tanabe Pharma Corporation https://www.tanabe-pharma.com/en/news/news20111118103040.html Fri, 18 Nov 2011 01:30:00 GMT 4b6b7130-ba3a-4014-9287-0358f7219d73 2011-11-18T01:30:00Z Revision of Dividend of Retained Earnings and Year-end Dividend Forecast https://www.tanabe-pharma.com/en/news/news20111031103040.html Mon, 31 Oct 2011 01:30:00 GMT 1701ab17-8ced-4c8e-8ebd-9a6f13640fb4 2011-10-31T01:30:00Z Formulation of Medium-Term Management Plan 11-15 New Value Creation https://www.tanabe-pharma.com/en/news/news20111017100031.html Mon, 17 Oct 2011 01:30:00 GMT b46439fa-f794-4761-abad-88982ec7eee8 2011-10-17T01:30:00Z ＜Presentation Material＞ https://www.tanabe-pharma.com/en/news/news20111017102995.html Mon, 17 Oct 2011 01:29:00 GMT 9d77fc36-b8fa-4deb-adfd-833994473ff0 2011-10-17T01:29:00Z Toray, Mitsubishi Tanabe Pharma Reach North American License Agreement on Antipruritic Agent, TRK-820 https://www.tanabe-pharma.com/en/news/news20111014103047.html Fri, 14 Oct 2011 01:30:00 GMT 9d80cadf-4316-42d3-a741-97d311a8f364 2011-10-14T01:30:00Z Approval for "IMUSERA® Capsules 0.5mg" Japan's First Once-Daily Oral Dosing Multiple Sclerosis Treatment https://www.tanabe-pharma.com/en/news/news20110926103086.html Mon, 26 Sep 2011 01:30:00 GMT 53b8da70-50a6-4344-9614-af2d9661567b 2011-09-26T01:30:00Z Approval for TELAVIC® 250mg Tablet Novel Mode of Action for Chronic Hepatitis C Treatment https://www.tanabe-pharma.com/en/news/news20110926102968.html Mon, 26 Sep 2011 01:29:00 GMT 67cd3a78-33e2-4981-a0f1-d8bfe2b5a33b 2011-09-26T01:29:00Z Approval for Additional Indication of Generalized Myasthenia Gravis Venoglobulin® IH 5% for Intravenous Injection, a Human Immunoglobulin Preparation Derived from Donated Plasma https://www.tanabe-pharma.com/en/news/news20110926102840.html Mon, 26 Sep 2011 01:28:00 GMT 1ee3e1da-17ab-4d86-b7bd-e9937b6218bd 2011-09-26T01:28:00Z Launch of "SIMPONI® (golimumab) Subcutaneous Injection 50mg Syringe" A Treatment of Rheumatoid Arthritis https://www.tanabe-pharma.com/en/news/news20110915103051.html Thu, 15 Sep 2011 01:30:00 GMT 75c8340b-aa34-4b42-916f-a045b33c1273 2011-09-15T01:30:00Z New Drug Application Filed in Japan for MP-513 a Type 2 Diabetes Treatment https://www.tanabe-pharma.com/en/news/news20110901103022.html Thu, 01 Sep 2011 01:30:00 GMT 1fafe1db-bed1-4ffc-9fcd-0cccdd094c8a 2011-09-01T01:30:00Z Mitsubishi Tanabe Pharma Prevails in U.S. Argatroban Patent Litigation https://www.tanabe-pharma.com/en/news/news20110822103092.html Mon, 22 Aug 2011 01:30:00 GMT ca0e0e68-71d5-48de-8a62-f39b2b8500f4 2011-08-22T01:30:00Z Remicade® for I.V. Infusion 100, Anti-Human TNF α Monoclonal-Antibody Approval for a Partial Change of Dosage and Usage in Crohn’s Disease https://www.tanabe-pharma.com/en/news/news20110817103025.html Wed, 17 Aug 2011 01:30:00 GMT f94f71dd-0048-47f2-b956-4f2537db050e 2011-08-17T01:30:00Z Revision to First Half and Full Year Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2012 https://www.tanabe-pharma.com/en/news/news20110729103047.html Fri, 29 Jul 2011 01:30:00 GMT b0945cb8-004b-44a9-ab38-44a55a63d0a2 2011-07-29T01:30:00Z The NHI Drug Price Listing and Launch of an Anti-depressant, Lexapro® 10mg https://www.tanabe-pharma.com/en/news/news20110721103096.html Thu, 21 Jul 2011 01:30:00 GMT 6026ab97-6be6-46d6-99e1-f5d836dce517 2011-07-21T01:30:00Z Notice Regarding a Business Suspension Order for the Ashikaga Plant of Mitsubishi Tanabe Pharma Factory Ltd. and a Business Improvement Order for Mitsubishi Tanabe Pharma Corporation https://www.tanabe-pharma.com/en/news/news20110719103029.html Tue, 19 Jul 2011 01:30:00 GMT 04b0f535-314c-4b1a-b694-04808e94d7c1 2011-07-19T01:30:00Z Approval for "SIMPONI® Subcutaneous Injection 50mg Syringe (Generic Name: Golimumab)" for Treatment of Rheumatoid Arthritis https://www.tanabe-pharma.com/en/news/news20110701103010.html Fri, 01 Jul 2011 01:30:00 GMT 1ec52eea-e096-4931-8a23-161a5fe8f0c6 2011-07-01T01:30:00Z Notice of a basic agreement between the Japanese Red Cross Society and Mitsubishi Tanabe Pharma Corporation regarding the commencement of discussions about the integration of their plasma fractionation operations https://www.tanabe-pharma.com/en/news/news20110617103043.html Fri, 17 Jun 2011 01:30:00 GMT 45ea5a8f-f298-4ae3-9c31-5475c90ba3f8 2011-06-17T01:30:00Z AZANIN® Tablets 50mg, Immunosuppressant Approval for Additional Indication for Refractory Rheumatic Diseases https://www.tanabe-pharma.com/en/news/news20110602103049.html Thu, 02 Jun 2011 01:30:00 GMT c982ade0-033c-4a6f-8166-223abbbe1247 2011-06-02T01:30:00Z Launch of Anti-allergy Agent, Bepotastine Besilate in China and Indonesia https://www.tanabe-pharma.com/en/news/news20110527103061.html Fri, 27 May 2011 01:30:00 GMT bf1d2f6e-9187-4958-b77f-e00e595f0db7 2011-05-27T01:30:00Z Approval for Additional Indication for selective β1 antagonist, MAINTATE® Tablets 0.625, 2.5, and 5 and Launch of MAINTATE® Tablets 0.625 https://www.tanabe-pharma.com/en/news/news20110520103016.html Fri, 20 May 2011 01:30:00 GMT 7b8e654e-582c-41ca-96ef-434d3946a063 2011-05-20T01:30:00Z Approval for Additional Indications for the Selective Antithrombin Agents, Novastan® HI Injection 10 mg/2mL and Slonnon® HI Injection 10 mg/2mL https://www.tanabe-pharma.com/en/news/news20110520102935.html Fri, 20 May 2011 01:29:00 GMT 55cdee57-255c-4183-aa82-f6c9163d97e9 2011-05-20T01:29:00Z Approval for Additional Indication of Anti-D Human Immunoglobulin I.M.1000-BENESIS (Dry anti-Rho(D) Immune Human Globulin) https://www.tanabe-pharma.com/en/news/news20110520102839.html Fri, 20 May 2011 01:28:00 GMT 9ff222ec-df24-4177-9611-b98abe498f37 2011-05-20T01:28:00Z Partial Amendment of the Articles of Incorporation https://www.tanabe-pharma.com/en/news/news20110510103084.html Tue, 10 May 2011 01:30:00 GMT 0aa024ee-3c6d-463d-acc3-d41d031d54a8 2011-05-10T01:30:00Z Change of Directors, and Organization https://www.tanabe-pharma.com/en/news/news20110427103050.html Wed, 27 Apr 2011 01:30:00 GMT c4849174-0760-4511-ae33-9bc9a740bba9 2011-04-27T01:30:00Z Summary of the Quality Control Incident https://www.tanabe-pharma.com/en/news/news20110427102920.html Wed, 27 Apr 2011 01:29:00 GMT 11d1a2cc-56e7-4283-90cb-ace4d6a54cf3 2011-04-27T01:29:00Z Partial Return of Executive Compensation https://www.tanabe-pharma.com/en/news/news20110427102830.html Wed, 27 Apr 2011 01:28:00 GMT 60174993-90b1-4f9f-a6eb-ed97198b82a2 2011-04-27T01:28:00Z Impact of the Great East Japan Earthquake (3rd Notice) https://www.tanabe-pharma.com/en/news/news20110411103023.html Mon, 11 Apr 2011 01:30:00 GMT 801042a9-d111-40e3-8242-ac66ea89cd9c 2011-04-11T01:30:00Z Impact of the 2011 off the Pacific coast of Tohoku Earthquake (2nd Notice) https://www.tanabe-pharma.com/en/news/news20110330103058.html Wed, 30 Mar 2011 01:30:00 GMT bcb49c6d-87a5-43e1-8550-dea9072b6c6d 2011-03-30T01:30:00Z Novartis receives European Commission approval for FTY720, the first oral multiple sclerosis treatment for use in the EU https://www.tanabe-pharma.com/en/news/news20110328103018.html Mon, 28 Mar 2011 01:30:00 GMT afca7834-e36a-44c5-a069-fece9cbb1421 2011-03-28T01:30:00Z Impact of the 2011 off the Pacific coast of Tohoku Earthquake https://www.tanabe-pharma.com/en/news/news20110315103050.html Tue, 15 Mar 2011 01:30:00 GMT a7a10c3a-ecf3-4bd5-abbe-73df9e4d7128 2011-03-15T01:30:00Z Mitsubishi Tanabe Pharma Supports Japan Earthquake Relief Efforts https://www.tanabe-pharma.com/en/news/news20110314103080.html Mon, 14 Mar 2011 01:30:00 GMT 4ded73f6-de95-4f76-ab52-596ba3d28eaa 2011-03-14T01:30:00Z Open innovation laboratory for drug discovery and development by Mitsubishi Tanabe Pharma and Kyoto University -Basic and clinical research project for CKD drugs- https://www.tanabe-pharma.com/en/news/news20110311103093.html Fri, 11 Mar 2011 01:30:00 GMT eec61a2e-dfb9-45a9-adb5-62a64afb26a0 2011-03-11T01:30:00Z Transfer of Marketing Rights of 5 Long-term Listed Drugs to Tanabe Seiyaku Hanbai https://www.tanabe-pharma.com/en/news/news20110307103088.html Mon, 07 Mar 2011 01:30:00 GMT 7e6fe6d3-fae9-40ea-8e3e-a4de985c6e28 2011-03-07T01:30:00Z Application Submitted in Japan for MP-424 a Novel Chronic Hepatitis C Treatment https://www.tanabe-pharma.com/en/news/news20110128103079.html Fri, 28 Jan 2011 01:30:00 GMT 492b845d-64bc-47c9-9658-419588897db6 2011-01-28T01:30:00Z Nycomed and Mitsubishi Tanabe Pharma to Terminate Collaborative Development of APTA-2217, Roflumilast for Treatment of Respiratory Diseases in Japanese Market https://www.tanabe-pharma.com/en/news/news20110128102996.html Fri, 28 Jan 2011 01:29:00 GMT fe578666-8722-41ab-aa26-1a85af7b8480 2011-01-28T01:29:00Z Notice Regarding Voluntary Recall of Three Drugs (Six Dosage Sizes) https://www.tanabe-pharma.com/en/news/news20110126103046.html Wed, 26 Jan 2011 01:30:00 GMT 3c7a4418-cfa5-41cd-8c3d-45c684fc78bf 2011-01-26T01:30:00Z Kremezin®, Drug for Chronic Renal Failure Transfer of Marketing Rights in Japan https://www.tanabe-pharma.com/en/news/news20110111103092.html Tue, 11 Jan 2011 01:30:00 GMT 4870fc78-e356-4ade-b961-9302e73f3c9e 2011-01-11T01:30:00Z Out-Licensing of Bepotastine Besilate for Ophthalmic Use to a South Korea https://www.tanabe-pharma.com/en/news/news20101221103047.html Tue, 21 Dec 2010 01:30:00 GMT 06cf495e-781d-4c45-b3cc-ca44e1a8edee 2010-12-21T01:30:00Z Application Submitted in Japan for FTY720, a Novel Multiple Sclerosis Treatment https://www.tanabe-pharma.com/en/news/news20101220103073.html Mon, 20 Dec 2010 01:30:00 GMT 6482ab74-1ea0-4128-a7b9-867696838ec9 2010-12-20T01:30:00Z Commencement of R&D Partnership with Anaphore for Atrimer™ Technology (Novel Trivalent Proteins) https://www.tanabe-pharma.com/en/news/news20101214103019.html Tue, 14 Dec 2010 01:30:00 GMT cdb361a0-8581-4c27-b31d-75d72d38f869 2010-12-14T01:30:00Z Removal of Grace Period https://www.tanabe-pharma.com/en/news/news20101201103055.html Wed, 01 Dec 2010 01:30:00 GMT 7ca6ed50-93c4-4fa1-b0ad-b8d0d03e93bf 2010-12-01T01:30:00Z Notice Regarding Change in the Number of Shares Constituting One Trading Unit and Partial Amendments to the Articles of Incorporation https://www.tanabe-pharma.com/en/news/news20101029103045.html Fri, 29 Oct 2010 01:30:00 GMT bccf959a-f4e4-477d-8185-b2ee7c4e5739 2010-10-29T01:30:00Z Approval of additional indication of Venoglobulin® IH 5% I.V., human immunoglobulin G for the treatment of polymyositis and dermatomyositis https://www.tanabe-pharma.com/en/news/news20101027103087.html Wed, 27 Oct 2010 01:30:00 GMT e7d559bb-bbcc-495a-9b8e-82f002dce65f 2010-10-27T01:30:00Z Launch New 1000 mg Dosage Formulations of Pasil® and Pazucross® Injectable New Quinolone Antibacterial Agents on October 13 https://www.tanabe-pharma.com/en/news/news20101012103021.html Tue, 12 Oct 2010 01:30:00 GMT 6f86f017-42cb-48de-815a-e9fe8060fb79 2010-10-12T01:30:00Z Revision to First Half and Full Year Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2011 https://www.tanabe-pharma.com/en/news/news20101004103093.html Mon, 04 Oct 2010 01:30:00 GMT 54f8e873-70b1-4a1a-abbd-f19918658de6 2010-10-04T01:30:00Z Novartis gains NDA approval for FTY720 in the US https://www.tanabe-pharma.com/en/news/news20100928103060.html Tue, 28 Sep 2010 01:30:00 GMT 6c5f8647-ba6a-4d41-8952-6098afc993ad 2010-09-28T01:30:00Z Completes Post-Marketing Surveillance on All Patients with Refractory Uveoretinitis in Behcet's Disease REMICADE® I.V. Drip Infusion Anti-TNFα Monoclonal Antibody 100 https://www.tanabe-pharma.com/en/news/news20100818103039.html Wed, 18 Aug 2010 01:30:00 GMT 61671b59-9967-47f1-8468-43d416bce46e 2010-08-18T01:30:00Z Selective β1 Receptor Blocker "Kerlong® Tablets 5mg/10mg" Transfer of Manufacturing, Marketing, and Distribution Rights https://www.tanabe-pharma.com/en/news/news20100730103034.html Fri, 30 Jul 2010 01:30:00 GMT 3ef4aaf5-485c-4ef2-a7fd-e08fb9160aec 2010-07-30T01:30:00Z Revision to First Half Year Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2011 https://www.tanabe-pharma.com/en/news/news20100729103053.html Thu, 29 Jul 2010 01:30:00 GMT dae55ec1-311b-499f-8438-17567544969b 2010-07-29T01:30:00Z Approval for Partial Changes in Indications, Dosage and Usage, as well as New 1000 mg Dosage Formulation, for Injectable New Quinolone Antibacterial Agents, Pasil® and Pazucross® https://www.tanabe-pharma.com/en/news/news20100723103070.html Fri, 23 Jul 2010 01:30:00 GMT 8b6f5de3-f752-4618-ab29-4054c79ce0d0 2010-07-23T01:30:00Z GlaxoSmithKline and Mitsubishi Tanabe Pharma Corporation Terminates co-promotion of Adoair®, the combination drug for asthma and COPD https://www.tanabe-pharma.com/en/news/news20100701103047.html Thu, 01 Jul 2010 01:30:00 GMT e299ab11-971f-4c79-aae1-67fa9fccaf51 2010-07-01T01:30:00Z Approval of Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors https://www.tanabe-pharma.com/en/news/news20100618103026.html Fri, 18 Jun 2010 01:30:00 GMT 469fc2ca-4fd3-468f-a98c-097c8408b534 2010-06-18T01:30:00Z Approval for Additional Indication of Ulcerative Colitis for Remicade® I.V. Drip Infusion 100, Anti-Human TNF α Monoclonal-Antibody https://www.tanabe-pharma.com/en/news/news20100618102968.html Fri, 18 Jun 2010 01:29:00 GMT 0325bc4e-c269-4112-9704-844b432fff4e 2010-06-18T01:29:00Z Notice Regarding Submission of Business Improvement Plans https://www.tanabe-pharma.com/en/news/news20100616103099.html Wed, 16 Jun 2010 01:30:00 GMT b99c8baa-9f23-481f-8060-ea4ea2693ab0 2010-06-16T01:30:00Z Change of Representative Directors, Directors, and Organization https://www.tanabe-pharma.com/en/news/news20100512103084.html Wed, 12 May 2010 01:30:00 GMT 211b60d3-93a3-4677-b21a-518c7b31b73d 2010-05-12T01:30:00Z Partial Return of Executive Compensation https://www.tanabe-pharma.com/en/news/news20100512102977.html Wed, 12 May 2010 01:29:00 GMT 617129b9-ebbe-4feb-9778-f5f7aa0ed489 2010-05-12T01:29:00Z Notice Regarding Administrative Action Related to Violation of Pharmaceutical Affairs Law https://www.tanabe-pharma.com/en/news/news20100413103059.html Tue, 13 Apr 2010 01:30:00 GMT 41aa25bd-ef0c-4e99-8677-1df0ef73b748 2010-04-13T01:30:00Z Tianjin Tanabe Seiyaku Receives ISO 14001 Certification https://www.tanabe-pharma.com/en/news/news20100210103012.html Wed, 10 Feb 2010 01:30:00 GMT b4afab2e-7ed7-4ebe-866b-106fff92e12f 2010-02-10T01:30:00Z Mitsubishi Tanabe Pharma Supports Relief Efforts for Haiti Earthquake Disaster https://www.tanabe-pharma.com/en/news/news20100125103069.html Mon, 25 Jan 2010 01:30:00 GMT 6e1a71ca-92bc-4bec-974d-6f25b80e014a 2010-01-25T01:30:00Z Approval for Additional Indication of Psoriasis for Remicade® I.V. Drip Infusion 100, Anti-Human TNF-α Monoclonal-Antibody https://www.tanabe-pharma.com/en/news/news20100120103092.html Wed, 20 Jan 2010 01:30:00 GMT 51e68f9d-8570-4ccb-b76d-27c402b659d9 2010-01-20T01:30:00Z Approval for New Dosage Form of RADICUT®, Cerebral Neuroprotectant "RADICUT® BAG for I.V. infusion 30mg" https://www.tanabe-pharma.com/en/news/news20100119103035.html Tue, 19 Jan 2010 01:30:00 GMT e530bade-41d2-4851-85fd-6c65bf5d3dd9 2010-01-19T01:30:00Z Conclusion of Co-marketing Agreement for an Anti-Depressant, Escitalopram in Japan https://www.tanabe-pharma.com/en/news/news20100107103032.html Thu, 07 Jan 2010 01:30:00 GMT 2a2d7a9f-692b-4cb7-8969-cd7297e85115 2010-01-07T01:30:00Z